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Ferrocene-containing precursors, vinylferrocene and (E)-4-vinylferrocenylbenzaldehyde were 
prepared, by a Wittig olefination reaction and Heck cross-coupling reaction, respectively. Mononuclear 
ferrocenyl-derived imino complexes were synthesised by Schiff-base condensation reactions of (E)-4-
vinylferrocenylbenzaldehyde with various amines. This included the preparation of a silicon-containing 
derivative and its carbon analogue, to determine the effect of the lipophilic moiety on the biological 
activity. In addition, polynuclear ferrocenyl-derived imino complexes based on the tris(2-
aminoethyl)amine scaffold and the polypropyleneimine (PPI) first- and second-generation scaffolds 
were also synthesised using Schiff-base chemistry. These polynuclear complexes were prepared using 
template chemical procedures to that of the mononuclear complexes. The corresponding mono- and 
polynuclear ferrocenyl-derived amino complexes were synthesised via reductive amination reactions 
from the (E)-4-vinylferrocenylbenzaldehyde. The imine moiety was hydrogenated in order to compare 
the effect on the biological activity. The imino and amino complexes were isolated in moderate to high 
yields.  
A second series of ferrocenyl complexes was also prepared incorporating a thiosemicarbazone moiety, 
as this is a known pharmacophore and may confer favourable properties in terms of biological activity 
as well as solubility. Methyl hydrazinecarbodithioate was synthesised and reacted with the previously 
synthesised (E)-4-vinylferrocenylbenzaldehyde by a Schiff-base condensation reaction to afford a 
ferrocenyl dithiocarbamate. The dithiocarbamate was reacted with various amines via nucleophilic 
substitution reactions to give mono- and polynuclear ferrocenylthiosemicarbazone complexes. These 
complexes were isolated in low to moderate yields.  
All compounds were unequivocally characterised using various spectroscopic and analytical 
techniques, such as 1H, 13C{1H}, 31P{1H} Nuclear Magnetic Resonance (NMR) spectroscopy, Fourier 
Transform-Infrared (FT-IR) spectroscopy, elemental analysis and Electron Impact (EI)- or high 
resolution Electrospray Ionisation (ESI)-mass spectrometry. These methods confirmed the structural 
integrity of the proposed precursors and complexes.  
In vitro biological evaluations were carried out using the ferrocenyl-imino, ferrocenyl-amino and 
ferrocenylthiosemicarbazone complexes in order to investigate their potential antimycobacterial and 
antiplasmodial activity. Compounds were screened for their in vitro activity against the H37Rv strain 
of Mycobacterium tuberculosis and the chloroquine-sensitive (CQS) NF54 strain of Plasmodium 
falciparum. In the antimycobacterial evaluation, the ferrocenyl-amino complexes exhibited little to no 
activity compared to the ferrocenyl-imino complexes, which displayed moderate activity, giving 
minimum inhibitory concentration (MIC90) values in the micromolar range.  The trinuclear imino 
complex displayed the highest activity of the series, with an MIC90 value two-fold greater than that of 
ix 
 
ethambutol, a clinically available anti-TB drug. The higher generation polynuclear complexes (n = 4, 
8) could not be screened for antimycobacterial activity as they were not soluble at the tested 
concentration. The ferrocenylthiosemicarbazones, which displayed greater solubility than the imino and 
amino complexes, could all be tested and were also found to exhibit moderate antimycobacterial 
activity. The mononuclear complex and the octanuclear complex displayed the highest activity of this 
series. The incorporation of the pharmacologically active thiosemicarbazone moiety resulted in 
enhanced activity compared to the amino complexes, but decreased activity compared to the imino 
complexes. 
In the antiplasmodial screening against the NF54 strain of P. falciparum, the ferrocenyl-imino 
complexes displayed moderate antiplasmodial activity, with the octanuclear ferrocenyl-imino complex 
showing the best activity of the series. The mononuclear ferrocenylthiosemicarbazone complex 
displayed enhanced activity compared to the imino complexes. The ferrocenyl-amino complexes 
exhibited the best activity in the antiplasmodial screening, displaying IC50 values in the low micromolar 
range. The most active complex was the silicon-containing mononuclear derivative, which showed 
enhanced activity compared to its carbon analogue. The ferrocenylthiosemicarbazone complexes were 
also moderately active against P. falciparum, the mono- and trinuclear complexes exhibiting the highest 
activity of the series. As seen in the antimycobacterial screening, the thiosemicarbazone complexes 
were not the most active in the antiplasmodial screening. These complexes exhibited enhanced activity 
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Introduction and brief overview of metal-based antimycobacterial 
and antiplasmodial chemotherapies 
 
1.1 Problem Identification 
Microorganisms or microbes refer to single or multicellular microscopic organisms such as bacteria, 
viruses, fungi and the protozoa. Microbial diseases are caused (in humans or animals) by the 
introduction of one of these four organisms. Examples of such infectious diseases are tuberculosis 
(bacterial), malaria (protozoan), HIV/AIDS (viral), meningococcal meningitis (bacterial) and cholera 
(bacterial), which are all high priority diseases of the World Health Organisation (WHO) due to their 
worldwide burden.1 Malaria and tuberculosis remain a major global health problem affecting the 
developing world, causing an estimated 2 million deaths worldwide in 2012.2, 3  
Effective antituberculosis (anti-TB) and antimalarial treatments are known and are currently in use. 
However, the nature of microbes, by which they undergo random and specific mutations in order to 
survive, allows them to develop resistance to these treatments. This diminishes the efficacy of current 
treatments and these diseases remain prevalent and continue to spread. The emergence and spread of 
drug-resistant parasites is a major threat to disease control and new drug therapies and drug design 




1.2.1 Transmission and Worldwide Burden  
Tuberculosis (TB) is an infectious bacterial disease caused by the bacillus Mycobacterium tuberculosis 
(M. tuberculosis), typically infecting the lungs in the form of pulmonary TB. This bacterial pathogen 
caused 8.6 million new TB cases and 1.3 million TB deaths globally in 2012, and remains a major 
global health problem of great importance to the World Health Organisation (WHO).3 Fig. 1.1 shows 
the estimated TB incidence rates in 2012.  





Fig. 1.1: Estimated TB incidence rates in 2012.3 
 
1.2.2 TB Disease Pathogenesis 
Tuberculosis spreads with great ease, through the air, when people who are infected with active 
pulmonary TB expel bacteria. Inhalation of as little as a few droplet nuclei, 2 – 5 µm in diameter, 
containing as few as 1 – 3 tubercle bacilli is enough to result in the spread of TB infection.4 Infection 
occurs when these tubercle bacilli reach the alveoli of the lungs, where alveolar macrophages ingest the 
bacilli.5 An immune response is triggered and other white blood cells kill or encapsulate bacilli, forming 
a barrier shell called a granuloma, which keeps the bacilli under control. The majority of tubercle bacilli 
are then destroyed or inhibited.5 This process of inhibition of multiplication of the bacilli and halting of 
disease progression results in latent tuberculosis infection (LBTI).4, 5 However, if the immune system 
cannot keep the tubercle bacilli under control, some of the bacilli begin to multiply rapidly inside the 
macrophage (intracellularly), and TB disease has commenced. Ultimately the granuloma ruptures and 
spills many viable and infectious bacilli.5 Some of these bacilli may enter the lymphatic channels or the 
bloodstream and spread throughout the body to distant tissues and organs, particularly to the lymph 
nodes, apex of the lung, kidneys, brain and bone, where TB disease is most likely to develop.5 This 
process of dissemination triggers a further immune response and granulomas form at the tissues and 
organs where the bacilli have spread, allowing LTBI to be reestablished. Nevertheless, TB disease 
pathogenesis can occur at these areas as well in response to an inadequate immune response. 
 
1.2.3 Standard anti-TB drugs 
The first effective drug in the treatment of tuberculosis infections was the aminoglycoside antibiotic 
streptomycin. Initially used in monotherapy, streptomycin was quickly rendered less effective due to 
mycobacterial resistance to the drug. Other drugs, such as the antibiotic para-aminosalicylic acid and 




the nicotinamide analogue isoniazid, were also discovered to be active against Mycobacterium 
tuberculosis. Thus, ‘triple therapy’ was introduced, incorporating all three drugs in one regimen, over 
a period of twenty-four months. Over time, new classes of antimycobacterial drugs have been 
incorporated into the combination therapy in order to overcome resistance and shorten the duration of 
treatment. In addition, there are a number of other effective anti-TB drugs which are used as second-
line treatments or as cheaper alternatives. These include cycloserine, fluoroquinolones and the 
thiosemicarbazone-based thiacetazone. 
The current and most effective anti-TB therapy for drug-susceptible (DS)-TB comprises a six-month 
four-drug regimen.3, 4 Treatment involves the use of isoniazid, rifampicin, pyrazinamide and ethambutol 
as an initial phase for the first two months.3, 4 This is followed by a continuation phase of only isoniazid 
and rifampicin for the last four months.3, 4 All four drugs, whose structures are shown in Fig. 1.2, have 
different mechanisms of action, and all inevitably inhibit the growth of M. tuberculosis.4, 6 Isoniazid 
and pyrazinamide are prodrugs, which means that they are administered in an inactive or less active 









Fig. 1.2: Structures of drugs used in tuberculosis treatment i) isoniazid ii) pyrazinamide iii) rifampicin iv) 
ethambutol. 
 
Isoniazid (INH) enters the mycobacterial cell by passive diffusion through small water-filled pores in 
the cell membrane.7, 8 Here, INH undergoes oxidative activation by a catalase peroxidase to an 
isonicotinoyl radical, the active metabolite.7-10 These radicals react with co-factors to give INH-adducts, 
which inhibit the synthesis of nucleic acids, phospholipids and most importantly and mycolic acids.7-10 
Pyrazinamide (PZA), which is structurally similar to INH, gains access to the cell through passive 
diffusion as well as via ATP-dependent transport systems.8, 10 PZA is converted to its active form, 
pyrazinoic acid, by the pyrazinamidase enzyme. The mechanism of action of PZA is poorly understood, 
however, it is known to target semi-dormant tubercle bacilli present in acidic environments, resulting 
in reduced relapse rates in TB infections.8, 10   
Rifampicin, being highly lipophilic in nature, easily diffuses across the cell membrane.8 The drug then 
binds to the mycobacterial DNA-dependent RNA polymerases with high affinity, thus inhibiting mRNA 




synthesis.8, 10 Ethambutol (EMB) is known to inhibit many cellular pathways of M. tuberculosis, such 
as mycolic acid transport, phospholipid synthesis, RNA metabolism and spermidine biosynthesis.8, 10 
However, the target crucial to its antimycobacterial activity is the inhibition of arabinogalactan 
biosynthesis, an important structural component of the cell wall. This is achieved by prevention of 
arabinan polymerisation.8, 10 
 
1.2.4 Mycobacterial drug-resistance 
The four-drug regimen of isoniazid, pyrazinamide, rifampicin and ethambutol as an anti-TB treatment 
is highly effective, however, due to the ability of bacteria to undergo minor mutations coupled with the 
misuse of drug therapies, M. tuberculosis has developed resistance to some of these drugs. Thus, there 
are different strains of M. tuberculosis with varying levels of resistance. Multidrug-resistant (MDR)-
TB is a strain which is resistant to the two most important first-line anti-TB drugs, isoniazid and 
rifampicin.4 Extensively drug-resistant tuberculosis is resistant to isoniazid, rifampicin, all 
fluoroquinolones and all second-line injectable drugs.4 
The mechanism of resistance development in M. tuberculosis strains against current anti-TB agents has 
a genetic basis.11 An approach of gene sequencing and analysis of specific drug-resistant TB strains was 
used in order to determine the reason for resistance.11 The mutated genes or mutations that are associated 
with resistance to specific anti-TB drugs are shown in Table 1.1.  
 
Table 1.1: Summary of the molecular mechanisms of drug-resistance.11  
Drug Associated mutated gene or mutation 
Isoniazid katC, inhA, oxyR, ahpC, furA 
Rifampicin rpoB 
Pyrazinamide pncA, IS6110 insertion 
Ethambutol embB 
Streptomycin rrs, rpsL 
Fluoroquinolones gyrA, gyrB 
 
  





1.3.1 Parasite strains and life cycle 
Malaria is an infectious parasitic disease caused by protists of the Plasmodium genus and transmitted 
by the female Anopheles mosquito. There are five Plasmodium species that cause malaria; P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi, which cause malaria of varying severities.12-
14 The life cycle of the malaria parasite requires two hosts for completion,13 as represented in Fig. 1.3. 
It involves a continuous cycle of red blood cell invasion, parasite replication, cell rupture, and 
reinvasion.  Of these different stages, the parasite is only pathogenic when it is in the host’s bloodstream, 
known as the blood stage, which is responsible for the symptoms and deadly consequence of the 
disease.13, 14  
 
Fig. 1.3: Life cycle of the malaria parasite.14 
 
1.3.2 Malaria disease pathogenesis 
During the blood stage, the malaria parasites invade erythrocytes and ingest large amounts (60 – 80 %) 
of host cell haemoglobin in order to complete its life and survive.13, 14 By a phagocytosis-like 
mechanism, the trophozoite and early shizont parasite forms ingest and transport the haemoglobin to 
the digestive food vacuole.13, 14 This acidic, proteolytic organelle with a pH in the range 5.0 – 5.4 and 
containing a wide range of proteases, is thought to be specialised for the purpose of haemoglobin 
degradation.13, 14 The proteases can be divided into four groups: aspartic proteases, cysteine proteases, 




a histoaspartic protease, and a zinc metalloprotease. These enzymes catabolise the haemoglobin 
tetramer in a systematic manner to produce peptide fragment and ultimately generating amino acids 
essential for parasite survival.13, 14 The process of haemoglobin degradation and haem detoxification is 
shown in Fig. 1.4. 
 
Fig. 1.4: Haemoglobin degradation and haem detoxification process by the malaria parasite.12 
 
This catabolism of haemoglobin also generates free haem, the iron centre of which is oxidized from 
Fe2+ to Fe3+ to give aquaferriprotoporphyrin IX (H2O-Fe(III)PPIX) as a by-product, which is toxic to 
the malaria parasite.13, 14 This haem species is harmful to the parasite as it may cause enzyme inhibition, 
peroxidation of membranes, production of free oxygen radicals and impaired leukocyte function.13, 14 
Thus, Plasmodium species have developed haem detoxification mechanisms or pathways. The most 
important of these mechanisms is the biocrystallisation of haem to form a highly insoluble, chemically 
inert substance called haemozoin or malaria pigment, which accumulates in the food vacuole.13, 14    
 
1.3.3 Quinoline-based drugs 
In the past, treatment of malaria involved the use of quinoline-based organic drugs, with few side effects 
and toxicity. This includes drugs such as quinine, chloroquine, amodiaquine, piperaquine, primaquine 
and mefloquine (Fig. 1.5).12-14 Within the parasite’s life-cycle, quinoline-based antimalarials target the 
process of host cell haemoglobin catabolism to haemozoin, an important target in current antimalarial 
research, which takes place in the parasite’s acidic food vacuole.13, 14 Specifically, these drugs inhibit 
haemozoin formation, resulting in the accumulation of aquaferriprotoporphyrin IX which is toxic to the 
parasite.13, 14 
However, due to widespread resistance displayed by P. falciparum, which causes severe malaria, these 
drugs have been rendered ineffective. An example of this plasmodial resistance can be seen in the 




resistance to the once most effective antimalarial, chloroquine, which began to fail ten years after being 
put to use.13 Though the mechanism of resistance-development is not well characterised, what is known 







Fig. 1.5: Organic compounds used as antimalarials i) quinine ii) chloroquine iii) mefloquine.13, 14 
 
1.3.4 Antifolate drugs 
Another class of antimalarial drugs are the antifolates, which are formed by combinations or drug pairs 
composed of a sulfa drug (sulfadoxine, sulfalene or dapsone) and either pyrimethamine, proguanil or 
chlorproguanil, used in fixed ratio combinations.13, 14 Antifolate drug combinations (Fig. 1.6) interfere 
with parasite metabolism, by specifically inhibiting the formation of folate, a substance vital for malaria 
parasite survival. The drug combinations incorporate a drug which is a dihydrofolate reductase (DHFR) 
inhibitor and another which is a dihydropteroate synthase (DHPS) inhibitor, which in turn impedes the 




















These antifolate drugs have also shown susceptibility to resistant malaria parasite strains. The 
mechanism of resistance by the parasite is the development of point mutations in the two antifolate drug 
target enzymes in the folate biosynthetic pathway, DHFR and DHPS.13, 16 
 
1.3.5 Artemisinin-based combination therapy 
The most effective antimalarial treatment currently in use for P. falciparum infections is artemisinin-
based combination therapy (ACT).14, 17 Artemisinin is isolated from the Chinese sweet wormwood plant, 
which was traditionally used to treat fever. Artemisinin and its derivatives (Fig. 1.7) are a group of 
highly effective drugs, capable of rapid elimination of malaria parasites.14, 18 ACT is therapy 
incorporating artemisinin or an artemisinin derivative and a second drug with a different mechanism of 
action, the combination of which gives enhanced efficacy, while decreasing the risk of resistance 









Fig. 1.7: The structures of artemisinin and derivatives used in ACT, i) artemisinin ii) artemether iii) artesunate 
iv) dihydroartemisinin.14 
 
In contrast to quinoline-based antimalarials, artemisinin and its derivatives show antiparasitic activity 
at all stages of the parasite’s life cycle.19 These drugs show antiplasmodial effects in the liver stages 
(asexual pre-erythrocytic) and blood stages (erythrocytic), as well as in the sexual stages (by killing 
gametes), decreasing transmission of infection.19 The multifaceted mode of action of these drugs may 
be the key to their efficiency. The exact mechanism of action is not fully understood, but the unusual 
peroxide bridge is thought to be essential to their antimalarial activity.19, 20 ACT is the most widely used 
antimalarial treatment; however, there have recently been reports of resistance and suspected resistance 
to these drugs.21-24  
 
  




1.4 Metal-based chemotherapy  
1.4.1 History and Motivation 
Medicinal inorganic chemistry is an interdisciplinary research field which has recently gained great 
interest, and involves the use of metal-based compounds as chemotherapeutic agents. Thought to have 
started with the discovery of Salvarsan (Arsphenamine), an arsenic-based chemotherapeutic agent used 
to treat syphilis,25 the field has grown significantly due to the success of the platinum-based anticancer 
drug cisplatin (cis-diamminedichloroplatinum(II)),26 shown in Fig. 1.8.  
 
 
Fig. 1.8: Structure of anticancer drug, cisplatin. 
 
Cisplatin and its second generation mononuclear derivatives, carboplatin and oxaliplatin, remain the 
most widely used drugs in cancer treatments, however, there are some drawbacks to their use.27 Their 
high toxicity, side effects and appearance of resistance in some cell lines has led to new approaches to 
make compounds with unique pharmacological properties.28-31 One such approach is the development 
of multinuclear complexes and an example of one such compound is Farrel’s BBR3464 (Fig. 1.9).32, 33 
This complex displayed higher in vitro cytotoxity than cisplatin and a mechanism of action different to 
that of cisplatin,32, 33 supporting the idea that multinuclearity may result in enhanced biological activity. 
However, BBR3464 was found to be highly toxic and phase IIb clinical trials were ceased.33 
 
Fig. 1.9: Structure trinuclear platinum complex, BBR3464. 
 
Other drug design approaches include ligand modification and the use of alternative metals to platinum 
(to decrease toxicity).29, 30, 34 Complexes incorporating transition metals such as the Platinum Group 
Metals (PGMs) – ruthenium, rhodium, palladium, osmium and iridium – are of particular interest as 
they are likely to show similar activity and lower toxicity to platinum. Metal-based chemotherapy has 
thus been well explored in anticancer research and current research has shown the application of these 
strategies in antimalarial research and more recently in antimycobacterial studies. 
 




1.4.2 Metal-based antimalarial agents 
Based on the increased activity of organic compounds incorporating metals, Wasi et al. synthesised and 
evaluated the antimalarial activity of metal complexes of amodiaquine and primaquine, however this 
did not enhance their activity.35 Following on from this, Sanchez-Delgado et al. designed metal-
chloroquine conjugates, aiming to increase antimalarial activity and overcome widespread resistance 
shown by P. falciparum.36, 37 Chloroquine (CQ) was modified with transition metals specifically 
because of their binding capability and reactivity brought about by the d orbitals.36, 37  
i) Rhodium conjugate 
A rhodium-chloroquine conjugate [RhCl(COD)CQ] (COD = 1,5-cyclooctadiene), shown in Fig. 1.10, 
was the first to be synthesised, characterised and biologically tested. CQ binds to Rh through the 
heteroaromatic (quinoline) nitrogen atom to form a 16 electron, square-planar complex. This complex 
exhibited in vitro antiplasmodial activities similar to that of chloroquine diphosphate (CQDP), while in 
vivo experiments showed that it caused a reduction in parasitemia of 94 % at a concentration at which 
CQDP caused 50 % reduction of parasitemia.36, 37  
 
Fig. 1.10: Structure of a rhodium-chloroquine conjugate, RhCl(COD)CQ.37 
 
These significant results demonstrated the potential of incorporation of metals into drugs of known 
therapeutic value, and the design was extended to incorporate a different metal centre, ruthenium, into 
the chloroquine organic scaffold.  
 
ii) Ruthenium-arene conjugates 
With the aim to increase biological activity, a Ru(II) binuclear chloroquine conjugate and Ru(ƞ6-arene) 
chloroquine conjugates, shown in Fig. 1.11, were synthesised. In these complexes, ruthenium is bound 
to chloroquine in the ƞ1-N mode, through the quinoline nitrogen, similar to the Rh-chloroquine 
conjugate (Fig. 1.10) These metal-chloroquine derivatives were tested and showed in vitro activity 
against CQ-sensitive and CQ-resistant strains of P. falciparum.36, 37 The complexes displayed 




consistently higher activity than CQDP in the sensitive strain, and enhanced activity in the resistant 








Fig. 1.11: Ruthenium(II) conjugates of chloroquine.12, 37 
 
iii) Ferroquine and ferrocenyl analogues 
In the continued search to increase biological activity through organometallic derivatisation, attention 
was turned to ferrocene, a small and rigid sandwich structure, for incorporation into known drug 
compounds. Ferrocene is a highly robust, neutral and chemically stable compound with low toxicity 
that can be easily derivatised and functionalised.38, 39 In general, metallocenes are known to exhibit a 
diverse array of biological activity and so it is not surprising that the ferrocenyl compounds are afforded 
interesting anti-tumour, antimalarial, antifungal and DNA-cleaving activity.38, 40 Ferrocene also has 
highly lipophilic properties, having the ability to interact with or effectively penetrate biological 
membranes, and exhibits unique electrochemical properties.38-40  





Fig. 1.12: Ferrocenyl analogues of known organic antimalarial agents.13 
 
Many ferrocenyl analogues of known organic antimalarial drugs, examples of which are shown in Fig. 
1.12, have been prepared and evaluated for their in vitro biological activity compared to the organic 
parent drug.13 Of these ferrocenyl analogues, the only significant result was seen in the case of the 
ferrocene-ciprofloxacin conjugate (Fig. 1.12, vi), where its activity exceeded that of the parent drug 
(ciprofloxacin) in CQ-resistant strains.13 
Following on from the important metal-chloroquine conjugate work by Sanchez-Delgado et al.,36, 37 
came the discovery, by Biot et al.,41 of ferroquine (7-chloro-4-[[[2-[N,N-dimethylamino)methyl]-N-
ferrocenyl]-methyl]amino]quinoline), a chloroquine derivative incorporating ferrocene into the lateral 
side chain.41 Ferroquine (FQ), shown in Fig. 1.13, has high in vitro activity in both the CQ-sensitive 
and CQ-resistant P. falciparum strains.41 In the CQ-sensitive strain, FQ proved as effective as CQDP 
(IC50 = 3.5 – 218 nM), while it was up to twenty times more effective than CQDP in the CQ-resistant 













with various Plasmodium strains.13, 41  The mechanism of antimalarial action is similar to that of 
chloroquine, involving the inhibition of haemazoin formation.12, 42 Ferroquine reached phase IIb clinical 
trials,43 being examined in malaria patients in an artemisinin-combined therapy (ACT) with artesunate.14 
It was thus shown that this organometallic derivatisation significantly increased the biological activity 
compared to the parent drug/compound.  
 
Fig. 1.13: Ferroquine, a ferrocenyl analogue of chloroquine.  
 
1.4.3 Metal-based antimycobacterial agents 
i) Ferrocene-containing compounds 
Owing to the success of ferroquine, ferrocenyl conjugation or modification as a drug design strategy is 
currently being applied and developed in the preparation of new antimycobacterial agents. Pelinski and 
co-workers reported the synthesis and antimycobacterial activity of ferrocenyl analogues of ethambutol 
and isoniazid, two important anti-TB drugs.44-46 In these studies, testing the in vitro activity against the 
H37Rv M. tuberculosis strain, two ferrocenyl diamines and two ferrocenyl acylhydrazones were found 
to be most active.44-46 The structures and minimum inhibitory concentration (MIC) values of these 
ferrocenyl compounds are shown in Fig. 1.14.  
 
 
i: MIC = 17.54 µM 
 
 
ii: MIC = 17.01 µM 
 
iii: R = H, MIC = 0.75 µM 
iv: R = CH3, MIC = 0.72 µM 
Fig. 1.14: Ferrocene-containing anti-TB agents and corresponding MIC values.44-46  
 
In the case of the ferrocenyl acylhydrazones, the antimycobacterial activity is similar to that of isoniazid 
(MIC ˃ 0.43 µM) and superior to that of ethambutol (MIC = 9.8 µM).46 This indicates that compounds 
based on the ferrocenyl polyamine scaffold may be of great significance in anti-TB research. 




ii) PGM-containing compounds 
Inorganic medicinal chemistry has also seen the introduction of PGM-based compounds as part of 
antimycobacterial therapeutic research. Historically, palladium compounds have previously been used 
in the treatment of tuberculosis. In the 1940s, doses of PdCl2 were administered daily with no apparent 
adverse effects in TB patients, but was found to be ineffective.47 More recently, Mauro and co-workers 
have reported several interesting examples of novel inorganic palladium(II) compounds,48-51 shown in 













Fig. 1.15: Novel palladium(II) compounds i) [Pd (C2, N-dmba)(X)(tu)] ii) [Pd(X)2(isn)2] iii) [Pd(C-
bzan)(SCN)(dppp)] iv) [Pd(μ-L)(N3)(PPh3)]2 
 
In an evaluation of these compounds’ antimycobacterial activity against the H37Rv M. tuberculosis 
strain, all displayed minimum inhibitory concentrations (MIC) in the micromolar range. With respect 
to the thiourea complexes (Fig. 1.15, i), the bromide analogue (MIC = 57.99 μM) proved more potent 
than the chloride analogue (MIC = 88.74 μM).48 The isonicotinamide complexes (Fig. 1.15, ii), 
displayed quite a broad MIC range (35.89 – 296.5 μM), with the azide analogue showing the highest 
activity.49 In comparison, the phosphine-containing palladium(II) complexes exhibited much higher 
activity, displaying MIC values of 5.15 μM for the mononuclear Pd(II)-phosphine complex (Fig. 1.15, 
iii)50 and 8.16 μM for the binuclear complex (Fig. 1.15, iv, L=Pz)51. These activities are similar or better 
than the MIC values of some commonly used anti-TB drugs, shown in Table 1.2. The higher 
X = Cl, N3, SCN, NCO 
X = Cl, Br 
L = Pz: R3 = H, R4 = H, R5 = H 
L = dmPz: R3 = CH3, R4 = H, R5 = CH3 
L = IPz: R3 = H, R4 = I, R5 = H 
 
iv 




antimycobacterial activitiy of these compounds could be attributed to their increased lipophilicity, 
brought about by the presence of lipophilic phosphine groups, as well as the chelating coordination of 
the other ligands.50-52  
 
Table 1.2: MIC values of some anti-TB drugs in the H37Rv strain.53 
Drug MIC range (µM) 
Gentamicin 4.14 – 8.38 
Tobramycin 8.56 – 17.11 
Clarithromycin 10.70 – 21.40 
Cycloserine 122.4 – 489.7 
 
 
Based on the clinical success of cisplatin (Fig. 1.8) and the great promise shown by the 
trinuclear analogue, BBR3464 (Fig. 1.9),32 research has shown several examples in which 
polynuclearity enhances biological activity.54-58 This may be due to increased biological 
interactions or more optimal chemical and physical properties. The ‘polynuclear’ approach can 
be applied to both organic- and metallodrugs and can be achieved by conjugating known 
pharmacophores onto dendritic scaffolds.54-58  
  




1.5 Dendrimer chemistry 
Dendrimer chemistry was first explored by Fritz Vogtle in 1978, dendrimers were then known as 
‘cascade molecules’.59 The term ‘dendrimer’ was first introduced in 1985, by Donald Tomalia, who 
synthesised the first family of such compounds.60 The word is derived from two Greek words, dendros 
meaning tree and meros meaning part, due to the resemblance of these molecules to the structure of a 
tree. In chemistry, dendrimers are defined as synthetic macromolecules with a repetitively branched 
molecular structure.61, 62 These molecules are monodisperse nanoscale polymers with defined molecular 
weights. Their hyperbranched nature results in highly multivalency, exposing a large number of 
functional groups on the surface of the molecule.    
 
1.5.1 Organic-based dendrimers 
Over the years, many different types of organic-based dendrimers (Fig. 1.16) have been developed:61, 62  
 Polyamido amino or PAMAM-dendrimers prepared by Tomalia,  
 Newkome’s arborols,  
 Frechet’s polyether dendrimers,  
 Poly (propylene imine) or PPI-dendrimers prepared by Meijer and Mulhaupt, 
 Moore’s phenylacetylene dendrimers. 
 
PAMAM dendrimer (G1) 
 
PPI dendrimer (G2) 
Fig. 1.16: Two most common dendrimer types, PAMAM- and PPI-dendrimers. 
 
These different dendrimer structures are synthesised in an algorithmic step-by-step manner using either 
divergent or convergent methods (Fig. 1.17).62 Divergent methods involve the assembly of the 
dendrimer from an internal multifunctional core, extending it outward to the eventual periphery (usually 
by a series of Michael additions). In convergent methods, the dendrimer is built from a starting 
monomer that ends up at the periphery and the structure is built inward to the internal core. Each 




repeated sequence of reactions producing a higher generation of the dendrimer.61, 63 With each increase 
in generation, the molecular weight of the dendrimer and the number of functional end groups are 
practically doubled. The multiple functional end-groups can be easily modified through simple organic 
reactions, which, in combination with the general properties of dendrimers affords them numerous 
applications in chemistry and biology.61, 62  
 
Fig. 1.17: Divergent (top) and convergent (bottom) dendrimer synthesis. 
 
1.5.2 Dendrimers in biology 
The property of dendrimers that makes them significant in biological systems is its multivalent surface 
(high concentration of functional groups on the periphery), which allows for maximum interaction with 
biological surroundings (e.g. substrates and receptors).62 Many dendrimers have also proven 
biologically compatible as they are non-toxic, non-immunogenic, biopermeable, target specific, and 
able to stay in biological circulation long enough to illicit the required clinical response.62 For these 
reasons, research has seen the application of dendrimers in medicinal chemistry and a number of these 
organic scaffolds have been studied as antiviral, antibacterial and antitumour dendrimers as well as 
dendrimer-based vaccines.61-63  
 
  





Transition metal derivatisation of organic-based dendrimers gives rise to metallodendrimers. In the past, 
research has been focused on the synthesis and characterisation of dendrimers, but more recently there 
has been a shift in focus to the various applications possible for these macromolecules.64 The 
incorporation of transition metals onto dendrimer scaffolds modifies its properties and functionality and 
thus opens up new areas of application such as catalysis,65 host-guest chemistry66 and extends the 
application in medicinal chemistry.67 There have been advances in biomedical sensing, photothermal 
sensing, photodynamic therapy and particularly their use as metal-based drugs.64  
Dendrimers as drugs offer a number of advantages with respect to control of effects within biological 
systems such as a high degree of molecular definition, versatility of drug design and multivalency of 
active motifs.62 In metallodendrimers, these effects may be compounded as the incorporation of metals 
increases reactivity and binding and has often been seen to increase biological activity in general.64, 68 
It has been observed that polynuclear complexes often display enhanced biological activity compared 
to their mononuclear analogues. This trend has been reported for metallodendrimers in the literature, 
and suggests that biological activity increases with molecular size.69, 70 There are numerous examples 
in the literature of the synthesis and antitumour activity of metallodendrimers, particularly those 
containing platinum, as a result of the success of cisplatin.64 The application of these macromolecules 
in antimalarial research is also on-going, but to a lesser extent in antibacterial research. There are 
currently no examples of metallodendrimers in the application of antimycobacterial studies reported in 
literature.  
With regards to metallodendrimers in antiplasmodial studies, Khanye and co-workers71 reported on the 
synthesis and antimalarial activity of ferrocenylthiosemicarbazones conjugated to the periphery of PPI-
dendritic scaffolds (Fig. 1.18).71 The ferrocenyl ligands and tetranuclear metallodendrimers were 
evaluated for antiplasmodial activity against a CQ-resistant strain of P. falciparum. The ferrocenyl 
thioester ligands displayed no antiplasmodial activity, while the two metallodendrimers (R = H, CH3) 
displayed good activity in the low micromolar range (IC50 = 2 – 7 µM).71  
 
Fig. 1.18: A tetranuclear ferrocenylthiosemicarbazone metallodendrimer. 
R = H, CH3 
 





New and growing resistance to past and current antiplasmoadial and antimycobacterial treatments has 
resulted in the need for new drug therapies and drug design strategies. The ferrocenyl moiety has proven 
a promising modification in the design of potential anticancer and antiplasmodial drug candidates. The 
use of ferrocene in medicinal chemistry is widespread and growing, however, its application in 
antimycobacterial research is in its infancy. With the use of metallodendrimers being relatively new in 
the fields of antiplasmodial and antimycobacterial research, this study aims to incorporate a number of 
chemical moieties with favourable properties onto macromolecular scaffolds, and evaluate these 
complexes as potential antimicrobial agents. This includes the ferrocene moiety, hydrophobic spacers, 
polyamines and thiosemicarbazones. The effect of the different chemical functionalities, as well as the 
nuclearity of the metallodendrimers, on the biological activity and properties are explored. 
 
 
1.7 Aims and Objectives 
1.7.1 General Aims 
The main aim of this project was to develop transition metal containing complexes based on polyamine 
(dendritic) macromolecular scaffolds, to complete full characterisation and evaluate their biological 
activity as potential antimycobacterial and antimalarial agents. 
 
1.7.2 Specific objectives 
In order to achieve this aim, this project had five main objectives: 
i) To synthesise ferrocenyl precursors; 72, 73 
 
Scheme 1.1: Structures of ferrocenyl precursors. 
 
ii) To prepare a series of novel polynuclear ferrocenyl-imino and -amino complexes as well 
as the corresponding mononuclear complexes; 
 
 












Scheme 1.2: Mono- and polynuclear ferrocenyl-imino and -amino complexes investigated in this project. 
 








Scheme 1.3: Mono- and polynuclear ferrocenylthiosemicarbazones investigated in this project. 
n = 3, 
n = 4, 
n = 8, 
n = 8, 
n = 4, 
n = 3, 




iv) To fully characterise all compounds using 1H and 13C{1H} Nuclear Magnetic Resonance 
and Infrared spectroscopy, mass spectrometry, elemental analysis or High Pressure Liquid 
Chromatography and determination of melting points. 
 
v) To investigate the utility of these polyamine/dendrimer-bound metal complexes as 
antimycobacterial and antimalarial agents against M. tuberculosis (H37Rv) and P. 
falciparum (NF54) strains, respectively. 
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Synthesis and characterisation of mono- and polynuclear 
ferrocenyl-derived imino and amino complexes 
 
2.1 Introduction 
In addition to incorporating metals into organic-based compounds as a drug design strategy as 
mentioned in chapter 1, the organic scaffolds of known drugs can also be further derivatised in order to 
enhance their potency. In this regard, in terms of antimycobacterial research, organic and 
organometallic analogues of the anti-TB drug ethambutol (Fig. 2.1) have been explored to some extent. 
Derivatisation of ethambutol (EMB) specifically has gained interest due to its low toxicity and chemical 
simplicity, as well as its quite efficient clinical anti-TB activity, which proves that the diamine backbone 
is a favourable framework.1 Thus far, studies that focused on the organic modification of EMB have 
seen the preparation of diamine and diaminoalcohol analogues thereof (Fig. 2.1), which have shown 










Fig. 2.1: Structure of ethambutol and three organic analogues. 
 
Based on the promising increased efficiency of these compounds, Pelinski and coworkers prepared a 
series of organometallic derivatives of EMB, employing different strategies to insert the ferrocene 
moiety as shown in Fig. 2.2.8, 9 Two of these analogues, in which ferrocenes replace the alcohol 
moieties, exhibited promising antitubercular activity, comparable to that of EMB.8, 9  
 





Fig. 2.2: Chemical modifications of EMB. 
 
Polyamines are compounds containing two or more primary amino groups, which show potential as 
drug delivery systems. Polyamines such as putrescine, spermidine and spermine are naturally occurring 
biomolecules essential for cellular growth and proliferation.10-13 Molecules of this kind enter the cell 
via a polyamine transporter (PAT), which also allows modified polyamines to pass through. Therefore, 
drug-polyamine conjugates are able to enter these cells, a strategy which has been used to penetrate 
tumour cells in anticancer research.14 However, polyamines as drug delivery scaffolds are also 
applicable in parasitic diseases, as they also show selective uptake in erythrocytes infected by the 
Plasmodium parasite.15, 16 Edwards and co-workers prepared a series of tetraamines of the general 
formula RNH(CH2)xNH(CH2)yNH(CH2)xNHR, which were evaluated for their antimalarial activity 
against Plasmodium falciparum.17 The dibenzyl analogues (R = benzyl) with optimum chain lengths (x 
= 3, y = 7) exhibited low micromolar IC50 values.17 
Thus, polyamines can be used as drug delivery systems in a similar way to some dendrimers. 
Dendrimers are highly branched, mono-disperse macromolecules with high multivalency, exposing a 
large number functional groups of the periphery of the molecule. One way in which dendrimers can act 
as drug delivery scaffolds is by covalent conjugation to drug compounds or active species.18-22 The 
dendrimer aids in transporting the drug into the cell or to the target site, where it is then degraded and 
the drug is released.18-22  
In this chapter, the synthesis and characterisation of a series of mono- and polynuclear ferrocenyl-
derived imino and amino complexes, based on the tris(2-aminoethyl)amine and polypropyleneimine 
(PPI) dendritic scaffolds, is described. All compounds were characterised using a range of spectroscopic 
and analytical techniques.  
 
  




2.2 Preparation of Ferrocene-containing precursors (2.2 – 2.3) 
2.2.1 Synthesis 
Two ferrocene-containing precursors (2.2 and 2.3) were prepared using literature methods23, 24 as shown 
in Scheme 2.1. Vinylferrocene (2.2) was synthesised via a Wittig olefination reaction, as described by 
Gallei et al.,23 in anhydrous tetrahydrofuran under inert conditions, and was isolated in 91 % yield as a 
bright orange crystalline solid. A Wittig olefination reaction allows for the preparation of an alkene by 
reaction of an aldehyde (or ketone) with a phosphonium ylide generated from the phosphonium salt.  
 
 
Scheme 2.1: Preparation of ferrocene-containing precursors. 
The first step of the Wittig olefination reaction involves the in situ generation of the phosphonium ylide 
by deprotonation of the methyl group of the phosphonium salt. In the second step, the nucleophilic 
carbon of the ylide attacks the electrophilic carbonyl carbon of ferrocenecarboxaldehyde. The reaction 
then proceeds via a four-membered heterocyclic ring intermediate to produce the alkene (the vinyl 
group of 2.2 in this case) as shown in Fig. 2.3. The melting point of 2.2 agrees with the range reported 
in literature.23  
 
Fig. 2.3: Mechanism of the Wittig olefination reaction.25 
Ferrocenyl-conjugate, (E)-4-vinylferrocenylbenzaldehyde (2.3), was prepared via a Heck cross-
coupling reaction of 1 with 4-bromobenzaldehyde, using a method utilised by Reyes Valderrama et al.24 








hours, and 2.3 was isolated in 52 % yield. However, the yield of this reaction was significantly improved 
by modifying the method and reagents, replacing 4-bromobenzaldehyde with 4-iodobenzaldehyde, as 
iodides are generally better leaving groups compared to bromides. The reagents were refluxed in 
acetonitrile and triethylamine under inert conditions for 24 hours (a reduced time) and afforded an 
improved 72 % yield. Compound 2.3 was isolated as a red crystalline solid and displays solubility in 
organic solvents as well as alcoholic solvents.  
The Heck cross-coupling reaction involves a catalytic cycle (Fig. 2.4) in which a Pd(0) active species 
catalyses a series of structural changes, ultimately producing the alkene product. In the cycle shown 
below, palladium acetate is reduced by tri-o-tolylphosphine to bis(tri-o-toylphosphine)palladium(0), the 
active species. Step A of the cycle is an oxidative addition reaction in which the palladium species 
inserts into the aryl-bromide bond of 4-bromobenzaldehyde. This is followed by formation of a pi-
complex of palladium with the alkene, vinylferrocene (2.2). In step B, by syn addition the alkene inserts 
into the Pd-C bond, which is followed by beta-hydride elimination in step C to give a new Pd-alkene 
pi-complex. Step D is reductive elimination by a base (triethylamine) to regenerate a Pd(0) species and 
the desired coupled product 2.3.  
 










1H Nuclear Magnetic Resonance Spectroscopy 
The 1H NMR spectrum of 2.2 (Fig. 2.5) displays peaks corresponding to the ferrocenyl protons; a singlet 
at 4.11 ppm, corresponding to the 5 protons of the unsubstituted cyclopentadienyl ring, and two triplets 
(4.21 and 4.36 ppm) for the protons of the monosubtituted cyclopentadienyl ring, as they are in different 
chemical environments. The spectrum shows a doublet-of-doublets at 6.46 ppm integrating for one 
proton, which corresponds to the alkenyl proton adjacent to the cyclopentadienyl ring. The two terminal 
alkenyl protons each give rise to a doublet-of-doublets (at 5.35 and 5.04 ppm respectively). This 
multiplicity is due to geminal and vicinal coupling experienced by these protons.  
 
 
Fig. 2.5: 1H NMR spectrum of 2.2 in CDCl3. 
 
The 1H NMR spectrum of 2.3 confirms the formation of the aldehyde with the presence of a singlet at 
9.97 ppm corresponding to the aldehyde proton. The four protons of the 1,4-substitiuted aromatic ring 
give rise to two doublets at 7.83 and 7.56 ppm respectively, with coupling constants of J ~ 8 Hz (Fig. 
2.6).  
 
Fig. 2.6: Cis and trans configurations and coupling constants observed in 2.3. 
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Evidence of C-C bond formation is shown in the absence of three alkenyl doublet-of-doublets (as 
observed for the vinyl protons in the 1H NMR spectrum of 2.2, Fig 2.5), and the presence of two doublets 
(at 7.07 and 6.73 ppm respectively) corresponding to the two protons of the alkene moiety. There are 
two stereoisomers possible for this structure, that with cis or trans configuration about the alkene group. 
However, the alkenyl doublets have vicinal coupling constants J ~ 16 Hz, confirming a trans 
configuration at the double bond (Fig. 2.6). The 1H NMR spectrum of 2.3 (Fig. 2.7) displays a pattern 
of peaks similar to that of 2.2 for the ferrocenyl protons. There are two triplets (4 protons of substituted 




Fig. 2.7: 1H NMR spectrum of 2.3 in CDCl3.  
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} NMR spectra of 2.2 and 2.3 each display the expected number of carbon signals, giving 
further evidence for their chemical structures. The spectrum of 2.2 displays signals at 134.82 and 111.19 
ppm corresponding to the carbon atoms of the vinyl group, with the carbon adjacent to the Cp ring lying 
most downfield. The ferrocenyl carbon atoms give rise to three signals, similar to the pattern seen in 
the 1H NMR spectrum of 2.2. The unsubstituted Cp carbon atoms give rise to one peak at 69.36 ppm, 
while the carbon atoms of the monosubstituted Cp ring give rise to two peaks (68.79 and 66.83 ppm). 
Furthermore, the spectrum shows a signal for the quaternary carbon atom of the substituted Cp ring at 
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The 13C{1H} NMR spectrum of 2.3 displays a peak corresponding to the carbonyl carbon atom at 191.67 
ppm, further confirming the presence of the aldehyde moiety. The spectrum also displays peaks at 
131.52 and 124.60 ppm for the carbon atoms of the alkene moiety. Further to this, the ferrocenyl Cp 
carbon atoms again give rise to three signals (at 69.99, 69.50 and 67.49 ppm respectively) and a fourth 
at 82.36 for the quarternary Cp carbon. The six aromatic carbon atoms are observed as four signals in 
the range 144 – 126 ppm, one signal for each quarternary carbon and another for each pair of equivalent 
carbons of the 1,4-disubstituted aromatic ring.  
 
Infrared Spectroscopy 
Infrared (IR) spectral analysis provides further evidence supporting the synthesis of these ferrocenyl 
precursors (2.2 and 2.3). The different absorption bands observed attest to the composition of the 
compounds and are in accordance with literature data. Figure 2.8 shows the region from 1600 – 1700 
cm-1 is important for 2.2 and 2.3. The presence of a ν(C=C) absorption band at 1630 cm-1 in the IR 
spectrum of 2.2 confirms the alkene moiety of the vinyl group. In the IR spectrum of 2.3, the ν(C=C) 
band for the alkene is retained at 1630 cm-1, while the ν(C=O) absorption band for the aldehyde moiety 
is observed at 1693 cm-1 for 2.3. 
 
Fig. 2.8: IR spectra of 2.2 (top) and 2.3 (bottom). 
 











C=C (1630 cm-1) 
C=C (1630 cm-1) 
C=O (1693 cm-1) 





Furthermore, the Electron Impact (EI)-mass spectra of 2.2 and 2.3, each shows a base peak 
corresponding to [M]+, 212 m/z for 2.2 and 316 m/z for 2.3, further confirming that the desired 
compounds were obtained. 
 
2.3 Synthesis of Mono- and Polynuclear Ferrocenyl-derived imino complexes (2.4 – 2.9) 
 
2.3.1 Mononuclear complexes (2.4 – 2.6) 
2.3.1.1 Synthesis 
(E)-4-vinylferrocenylbenzaldehyde (2.3) was then used in the synthesis of mononuclear ferrocenyl-
imino complexes (2.4 – 2.6). This was achieved by Schiff-base condensation reactions of 2.3 with 
various amines in methanol at 40 °C (Scheme 2.2). Compounds 2.4 – 2.6 were isolated as red powders 
in good yields (83 – 95 %). These complexes display solubility in a range of polar and non-polar 
solvents, as well as alcoholic solvents. 
 
Scheme 2.2: Preparation of mononuclear ferrocenyl imino complexes. (i) n-Propylamine / MeOH / 40 °C / 24 h; 
(ii) 2,2-Dimethyl-1-propanamine / MeOH / 40 °C / N2 /  48 h; (iii) (Trimethylsilyl)methylamine / MeOH / 40 °C / 
N2 / 48 h. 
A Schiff-base condensation reaction, the mechanism of which is shown in Fig. 2.9, involves the 
nucleophilic addition of an amine to a carbonyl group (aldehyde moiety of 2.3), followed by dehydration 
to give the Schiff-base or imine product. 
 
Fig. 2.9: Mechanism of a Schiff-base condensation reaction. 
i / ii / iii 
2.4: R = CH2CH2CH3 
2.5: R = CH2C(CH3)3 
2.6: R = CH2Si(CH3)3 
 





1H Nuclear Magnetic Resonance Spectroscopy 
The 1H NMR spectra of complexes 2.4 – 2.6, recorded in CDCl3, all displayed similar trends and 
patterns upon comparison. A representative example of a typical mononuclear imino complex is shown 
in Fig 2.10. The most important signal to note is the sharp singlet integrating for one proton, 
corresponding to the imine proton, in the region 8.25 – 8.11 ppm. This, along with the absence of the 
singlet corresponding to the aldehyde (at 9.97 ppm), gives evidence of complete imine bond formation 
(Schiff-base condensation). The two pairs of chemically identical aromatic protons each give rise to a 
doublet (region 7.71 – 7.45 ppm), while the two protons of the alkene moiety are each observed as a 
doublet between 6.95 and 6.71 ppm. Furthermore the spectra of 2.4 – 2.6 all display three signals for 
the ferrocenyl protons; a singlet integrating for the 5 protons of the unsubstituted Cp ring as well as two 
triplets for the two pairs of chemically equivalent protons of the substituted Cp ring. All of these signals 
occur at similar chemical shifts and with similar multiplicities and coupling constants to that of 
compound 2.3.  
 
 
Fig. 2.10: 1H NMR spectrum of 2.4, a representative example, in CDCl3. 
 
The aliphatic region for 2.4 – 2.6 differ slightly due to their varied alkyl chains. In the spectrum of 2.4 
(Fig. 2.10), the two groups of methylene protons of the propyl group are observed as a triplet (3.58 
ppm) and a multiplet (1.74 ppm) respectively, while the terminal methyl protons give rise to a triplet at 
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bond), which give rise to doublets integrating for two protons at 3.37 and 3.42 ppm respectively. The 
spectra of 2.5 and 2.6 also display a sharp singlet for the nine protons of the terminal trimethyl moiety. 
For 2.6, this singlet is significantly shielded (0.08 ppm compared to 0.99 ppm for 2.5, the carbon 
analogue), which is expected as the silicon atom is considerably more electron-donating than a carbon 
atom. 
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The imine carbon atoms of 2.4 – 2.6 give rise to signals between 160.68 and 158.04 ppm in the 
13C{1H}NMR spectra of these complexes. In addition, the spectra display peaks for the carbon atoms 
of the ferrocenyl Cp rings, the alkene and the aromatic groups, at similar chemical shift to that of 2.3. 
Signals for the alkyl carbon atoms are also seen between 29.70 and 1.03 ppm. 
 
Infrared Spectroscopy 
Further evidence for the presence of an imine bond is shown in the IR spectra of 2.4 – 2.6, which 
displays the characteristic imine ν(C=N) absorption band at 1628 cm-1 for all three complexes. In 
addition, the carbonyl ν(C=O) of the aldehyde moiety is not present in these spectra. The alkenyl ν(C=C) 
stretch is present at 1598 cm-1, a significantly lower wavenumber compared to the aldehyde precursor 
2.3. This is expected due to the electron-withdrawing nature of the new imine group.  
 
Mass Spectrometry 
The structures of 2.4 – 2.6 were further confirmed using EI-MS. The mass spectra of 2.4 – 2.6 each 
displays peak corresponding to the molecular ion [M+] at 357, 385 and 401 m/z respectively. 
 
  




2.3.2 Polynuclear complexes (2.7 – 2.9) 
2.3.2.1 Synthesis 
Polynuclear ferrocenyl-imino complexes (2.7 – 2.9) were subsequently synthesised by Schiff-base 
condensation reactions of 2.3 with various amines (tris-(2-aminoethyl)-amine or DAB-Am-4 or DAB-
Am-8) in methanol at 40 °C (Scheme 2.3), using a similar procedure to that for the preparation of 2.4 – 
2.6. Compounds 2.7 – 2.9 were isolated as orange powders in moderate to high yields (48 – 93 %), 





Scheme 2.3: Preparation of polynuclear ferrocenyl imino complexes. (i) Tris-(2-aminoethyl)-amine / MeOH / 




1H Nuclear Magnetic Resonance Spectroscopy  
The 1H NMR spectra of 2.7 – 2.9 all display peaks corresponding to protons of the ferrocenyl 
cyclopentadienyl (Cp) rings, alkenyl moeity and the aromatic ring with similar multiplicities, coupling 
constants and similar chemical shifts to that of compounds 2.4 – 2.6. All the 1H NMR spectra display a 
singlet in the range 8.07 – 8.24 ppm, corresponding to the imine protons of 2.7 – 2.9. The aliphatic 
region of the 1H NMR spectra of 2.7 – 2.9 due to their different dendritic cores. The protons of the three 
ethylene branches of 2.7 are observed as two triplets (3.69 and 2.94 ppm) in the spectrum (Fig. 2.11), 
each integrating for the six protons that are in the same chemical environment.  
i / ii / iii 
2.7: n = 3, 
2.8: n = 4, 
2.9: n = 8, 















Fig. 2.11: 1H NMR spectrum of 2.7 in CDCl3.  
 
In the 1H NMR spectrum of the first generation metallodendrimer 2.8 (Fig. 2.12), the protons of the 
aliphatic core and four aliphatic branches give rise to five signals in the region 1.44 – 3.63 ppm and are 
assigned as shown in the spectrum below. The 1H NMR spectrum of 2.9 displays six peaks in the region 




































Chemical shift (ppm) 
Chemical shift (ppm) 




13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} NMR spectra of 2.7 – 2.9 display peaks corresponding to the ferrocenyl carbon atoms, 
alkenyl carbon atoms and aromatic carbon atoms. The signal for the imine carbon atoms are observed 
between 161.74 and 160.74 ppm. Furthermore, the carbon atoms of the various aliphatic/dendritic 
branches and cores are also observed in the spectrum in the range 60.46 – 25.28 ppm.  
 
Infrared Spectroscopy 
The IR spectra of 2.7 – 2.9 display further evidence of the presence of the imine bond with the presence 
of an imine ν(C=N) absorption band at ~1630 cm-1 for all three complexes. An alkenyl ν(C=C) stretch 




High resolution Electrospray Ionisation (ESI) mass spectral analysis was used to confirm the structures 
of 2.7 – 2.9. The mass spectrum of 2.7 displays peaks at m/z 1041.2966 ([M+H]+), m/z 521.1527 
([M+2H]2+) and m/z 347.7709 ([M+3H]3+), confirming its structure. In the mass spectrum of 2.8, a peak 
corresponding to [M+2CH3CN+4H]4+ is observed at m/z 399.2807. Furthermore, the spectrum of 2.9 








2.4 Synthesis of Mono- and Polynuclear Ferrocenyl-derived amino complexes (2.10 – 2.15) 
 
2.4.1 Mononuclear complexes (2.10 – 2.12) 
2.4.1.1  Synthesis 
The next synthetic step was the preparation of the corresponding amines of compounds 2.4 – 2.9. 
Mononuclear amino complex 2.10 was initially synthesised by reduction of the imine bond of 
mononuclear complex 2.4. This was achieved via hydrogenation, by reacting 2.4 with sodium 
borohydride in methanol (Scheme 2.4). Compound 2.10 was isolated as an orange solid, differing in 
colour compared to the corresponding dark red imine precursor, in 50 % yield.  
 
Scheme 2.4: Synthetic route to mononuclear complex 2.10.  
 
In efforts to improve the low yield of this reaction, all subsequent reactions to produce the amine 
complexes were performed in a one-pot reductive amination from the aldehyde (2.3), without isolating 
the intermediate imine complex as shown in Scheme 2.5. Compounds 2.10 – 2.12 were synthesised in 
a one-pot reaction in which a ferrocenyl-aldehyde (2.3) underwent a Schiff-base condensation reaction 
with various amines to give the corresponding ferrocenyl-imine (not isolated), followed by reduction 
with sodium borohydride to afford the ferrocenyl-amines (2.10 – 2.12). All mononuclear complexes 
were isolated as red or orange solids, displaying solubility in a range of polar and non-polar solvents.   
 
 
Scheme 2.5: One-pot synthesis of mononuclear ferrocenyl-derived amino complexes. (i) Propylamine or 2,2-





2.10: R = CH2CH2CH3 
2.11: R = CH2C(CH3)3 
2.12: R = CH2Si(CH3)3 
 





1H Nuclear Magnetic Resonance Spectroscopy 
The 1H NMR spectra of 2.10 – 2.12 (Fig. 2.13) display peaks corresponding to the protons of the 
ferrocenyl Cp rings, the alkene group and the aromatic protons with similar multiplicities and coupling 
constants to their corresponding imino complexes (2.4 – 2.6). However, these peaks are all shifted 
slightly upfield (protons are more shielded) compared to the ferrocenyl-imino complexes (2.4 – 2.6). 
This is due to the relative electron-withdrawing effects of the imine bond compared to the amine bond. 
The imino moiety is more electron-withdrawing than the amino moiety, resulting in a more deshielding 
effect on the protons in complexes 2.4 – 2.6.  
 
 
Fig. 2.13: Stacked 1H NMR spectra of 2.10 – 2.12 in CDCl3. 
 
Evidence of reductive amination is displayed in the 1H NMR spectra of 2.10 – 2.12.  The spectra do not 
display a peak (singlet) corresponding to an aldehyde proton (~10 ppm) or an imine proton (~8 ppm), 
indicating successful and complete conversion to the amine. Furthermore, the two new methylene 
protons, adjacent to the aromatic ring and the new amine nitrogen, are observed as a singlet at between 
3.81 – 3.79 ppm, confirming hydrogenation of the imine. These trends are consistent for all 
mononuclear complexes 2.10 – 2.12. 
Chemical shift (ppm) 




In the 1H NMR spectrum of 2.10, the methylene protons of the propyl group give rise to a triplet (2.62 
ppm) and a multiplet (1.55 ppm), while the methyl protons are observed as a triplet at 0.93 ppm. These 
three signals are shifted significantly upfield compared to the imine precursor. This is expected due to 
the inductive effects of the different functional groups; the imine moiety is more electron-withdrawing 
than the amine moiety.  
For 2.11, the signal for the two methylene protons adjacent to the amine nitrogen and quaternary carbon 
is seen at 2.37 ppm (singlet), while the nine terminal methyl protons give rise to a singlet at 0.93 ppm. 
In the 1H NMR spectrum of 2.12, the methylene protons adjacent to the silicon atom give rise to a 
singlet at 2.08 ppm, while the spectrum displays a singlet at 0.07 ppm corresponding to the protons of 
the methyl group. These protons are significantly shielded (upfield) compared to its carbon analogue 
(10), as a result of the electron-donating effect of the silicon atom.  
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} spectra of 2.10 – 2.12 display all the expected peaks for the aromatic, ferrocenyl and alkene 
carbon atoms, at similar chemical shifts to that in the corresponding imino complexes 2.4 – 2.6. In the 
13C{1H} spectrum of 2.4, the carbon  atom between the aromatic ring and the new amine nitrogen gives 
rise to a significantly deshielded peak at ~161 ppm, which is not present in that of 2.10 – 2.12. Instead, 
in the spectra of 2.10 – 2.12, this carbon atom is now a methylene carbon and is observed as a relatively 




The infrared spectra of 2.10 – 2.12 give further evidence of reductive amination. The ν(C=O) and 
ν(C=N) absorption bands of the precursor (2.3) and intermediates (2.4 – 2.6) respectively, are not 
present in these spectra. In addition, a ν(N-H) stretching vibration is displayed between 3298 – 3279 
cm-1 and a ν(N-H) bending vibration around 1633 – 1631 cm-1, confirming the presence of the amine 
group. A ν(C=C) absorption band is observed for the alkene moiety between 1611 – 1607 cm-1, shifted 
to slightly higher wavenumbers (compared to 2.4 – 2.6) as a result of the electron-donating nature of 
the new amine moiety.   
  





Electron Impact mass spectrometry was used to confirm the structures of 2.10 – 2.12. The base peak in 
the mass spectra of 2.10 – 2.12 each corresponds to the molecular ion [M+]. These occur at 359, 387 
and 403 m/z respectively. 
 
2.4.2 Polynuclear Complexes (2.13 – 2.15) 
2.4.2.1 Synthesis 
Compounds 2.13 – 2.15 were each synthesised in a one-pot reaction in which the ferrocenyl-aldehyde 
(2) underwent a Schiff-base condensation reaction with various amines (tris-(2-aminoethyl)-amine or 
DAB-Am-4 or DAB-Am-8) to give the corresponding ferrocenyl-imine (not isolated), followed by a 
reduction with sodium borohydride to afford the ferrocenyl-amine (2.13 – 2.15). All polynuclear 
complexes were isolated as orange powders in moderate yields, displaying solubility in a range of 






Scheme 2.6: One-pot synthesis of polynuclear ferrocenyl-derived amino complexes. (i) Tris-(2-aminoethyl)-
amine / MeOH / 40 °C / 22 h or DAB-Am-4 / MeOH / 40 °C / 36 h or DAB-Am-8, MeOH / 40 °C / 36 h. (ii) 





2.13: n = 3, 
2.14: n = 4, 
2.15: n = 8, 





1H Nuclear Magnetic Resonance Spectroscopy 
As with the mononuclear complexes 2.10 – 2.12, the 1H NMR spectra of 2.13 – 2.15 display peaks 
corresponding to the protons of the ferrocenyl Cp rings (4.45 – 4.13 ppm), the alkene group (6.90 – 
6.65 ppm) and the aromatic protons (7.40 – 7.25 ppm) with similar multiplicities and coupling constants 
to their imine precursors (2.7 – 2.9). Again, the peaks are shifted upfield compared to the imine 
precursors as a result of the lessened electron-withdrawing nature of the amine group. The 1H NMR 
spectrum of 2.14 is shown in Fig. 2.14 as a representative example. The spectra of 2.13 – 2.15 do not 
display a singlet corresponding to an aldehyde proton (~10 ppm) or an imine proton (~8 ppm) of the 
precursors. Furthermore, all spectra display a broad singlet assigned to the methylene protons adjacent 
to the amine nitrogen and aromatic ring (region 3.74 – 3.73 ppm), confirming hydrogenation/reduction.  
 
 
Fig. 2.14: 1H NMR spectrum of 2.14, a first generation ferrocenyl dendrimer, in CDCl3. 
 
The 1H NMR spectra of 2.13 – 2.15 display broadening and overlapping signals, which is characteristic 
of dendritic ligands of this type. The signals for the protons of the aliphatic core and branches of 2.13 
– 2.15 appear in the regions 2.69 – 2.61, 2.64 – 1.38 and 2.63 – 1.41 ppm, respectively. The 1H and 
13C{1H} NMR signals were assigned using 2D NMR methods, Correlation Spectroscopy (COSY) and 
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13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} spectra of 2.13 – 2.15 display the expected number of signals corresponding to the carbons 
of the aromatic group, ferrocenyl moiety and the alkene group in the expected regions. The singlet 
observed at ~160 ppm in the 13C {1H} spectra of ferrocenyl-imines 2.7 – 2.9, assigned to the imine 
carbon atom, is not observed in the spectra of 2.13 – 2.15. The presence of peaks between 53.99 – 53.97 
ppm for the newly hydrogenated carbon, adjacent to the aromatic ring and the amine nitrogen, further 
confirms that reductive amination has taken place. 
 
Infrared Spectroscopy 
The infrared spectra of the polynuclear complexes 2.13 – 2.15 are similar to that of the mononuclear 
complexes 2.10 – 2.12. A alkenyl ν(C=C) absorption band is observed at 1609 cm-1 as well as a ν(N-H) 
stretching and bending vibration at 3302 – 3283 cm-1 and 1607 – 1609 cm-1 respectively. 
 
Mass Spectrometry 
Mass spectral data of 2.13 – 2.15 further confirms the structures of these complexes. The high resolution 
ESI-mass spectrum of 2.13 displays a peak corresponding to [M+CH3OH+H]+ at m/z 1079.3688. The 




Two ferrocene-containing precursors, vinylferrocene (2.2) and (E)-4-vinylferrocenylbenzaldehyde 
(2.3) were prepared, by a Wittig olefination reaction and Heck cross-coupling reaction, respectively. 
Using the aldehyde 2.3, mononuclear ferrocenyl-derived imino complexes (2.4 – 2.6) were synthesised 
by Schiff-base condensation reactions with various amines. A silicon-containing derivative and its 
carbon analogue were also synthesised, in order to determine the effect of the lipophilic moiety on the 
biological activity compared to its organic analogue. Polynuclear ferrocenyl-derived imino complexes 
(2.7 – 2.9) based on the tris(2-aminoethyl)amine scaffold and the polypropyleneimine (PPI) first- and 
second-generation scaffolds were also synthesised using Schiff-base chemistry. These polynuclear 
complexes were prepared using similar chemical procedures to that of the mononuclear complexes. 
These afforded tri-, tetra- and octanuclear ferrocenyl complexes. The corresponding mono- and 
polynuclear ferrocenyl-derived amino complexes (2.10 – 2.15) were synthesised via reductive 




amination reactions from the aldehyde 2.3. The imine moiety was hydrogenated in order to compare 
the effect on the biological activity.  
The synthesised imino and amino complexes were isolated in moderate to high yields and were found 
to be stable in air and in solution. The mononuclear complexes were readily soluble in organic and 
alcoholic solvents, while the solubility of the polynuclear complexes was limited to organic solvents 
such as DCM, chloroform and ethyl acetate, as well partial solubility in DMSO. All complexes were 
characterised 1H, 13C{1H}, COSY and HSQC NMR spectroscopy, IR spectroscopy, elemental analysis 
and EI- or high-res ESI-mass spectrometry.  
 
 
2.6 Experimental  
2.6.1 Materials 
n-Butyllithium, ferrocenecarboxaldehyde, n-propylamine, tris(2-aminoethyl)-amine and DAB-Am-4 
were purchased from Sigma Aldrich. DAB-Am-8 was purchased from SymoChem. Solvents were 
purchased from Kimix and Merck and THF was dried by distillation. Methyltriphenylphosphonium 
iodide (2.1)27 and vinylferrocene (2.2)23 were prepared using modified literature procedures. 
 
2.6.2 Spectroscopic and Analytical Techniques 
Infrared (IR) absorptions were measured on a Perkin-Elmer Spectrum 100 FT-IR Spectrometer as KBr 
pellets or using Attenuated Total Reflectance (ATR). Nuclear Magnetic Resonance (NMR) Spectra 
were recorded on a Varian Unity XR400 MHz (1H at 399.95 MHz, 13C at 100.58 MHz, 31P at 161.90 
MHz), Varian Mercury XR300 MHz (1H at 300.08 MHz, 13C at 75.46 MHz, 31P at 121.47 MHz) or a 
Bruker Biospin GmbH (1H at 400.22 MHz, 13C at 100.64 MHz, 31P at 162.01 MHz) spectrometer at 30 
°C. Chemical shifts are reported using tetramethylsilane (TMS) as the internal standard. Elemental 
analysis for C, H and N were carried out using a Thermo Flash 1112 Series CHNS-O Analyser. Mass 
spectrometry determinations were carried out using Electron Impact (EI) on a JEOL GC Matell 
instrument or Electrospray Ionisation (ESI) on a Waters API Quattro Micro triple quadrupole mass 
spectrometer with data recorded using both the positive. Melting points were determined using a 
Reichert-Jung Thermovar or a Büchi Melting Point Apparatus B-540. Compound 2.10 was analysed by 
HPLC using an Xbridge C18 (4.6 × 150 mm) 5 μm column; 2.0 μL injection volume; flow 0.7 mL 
min−1; gradient: 30–100% B in 15 min (hold 2 min) (Mobile phase A: 10 nM NH4OAc in H2O and 
Mobile phase B: 10 nM NH4OAc in methanol) with a Thermo Separation Products (TSP), Spectra 
SERIES P200 pump UV100 detector set at 254 nm. 
 




2.6.3 Synthesis of precursors 
2.6.3.1 Methyltriphenylphosphonium iodide (2.1)27 
 
Iodomethane (1.32 mL, 21.1 mmol) dissolved in 20 mL of diethyl ether was added to a stirring solution 
of triphenylphosphine (5.61 mL, 21.4 mmol) in 30 mL of diethyl ether and the reaction mixture was 
stirred at room temperature for 12 hours. The desired product 2.1 formed as a white precipitate, which 
was collected by suction filtration and washed with diethyl ether. Yield: 8.21 g, 95.0 %. 1H NMR 
(400.22 MHz, CDCl3): δ (ppm) = 7.76 (m, 6H, Hb), 7.75 (m, 3H, Ha), 7.73 (m, 6H, Hc), 3.11(m, 3H, 
Hd). 31P{1H} NMR (162.01 MHz, CDCl3): δ (ppm) = 22.61 (s, 1P).  
 
2.6.3.2 Vinylferrocene (2.2)23 
 
n-Butyllithium (3.79 mL, 9.48 mmol) was added dropwise to a stirring solution of 2.1 (2.55 g, 6.32 
mmol) in dry THF (80 mL) at -78 °C. The resulting bright yellow suspension was then warmed to room 
temperature and stirred for 2 hours. A solution of ferrocenecarboxaldehyde (1.00 g, 4.67 mmol) in dry 
THF (20 mL) was added dropwise to the suspension at -78 °C and the resulting dull red reaction mixture 
was warmed to room temperature and stirred for 20 hours. Following stirring, the reaction mixture was 
quenched with a saturated solution of ammonium chloride (50 mL) at 0 °C. The organic layer was 
separated and the aqueous layer was washed with diethyl ether (3 x 50 mL). The organic fractions were 
combined, stirred over anhydrous magnesium sulfate and filtered by gravity. The solvent of the filtrate 
was reduced and excess diethyl ether was added. A brown precipitate was observed and filtered by 
gravity. The solvent was then removed to give a bright orange-red residue. The product was then 
purified by column chromatography using 100 % petroleum ether (40 – 60 °C) as the eluent, with the 
desired product eluted first. The fractions containing the desired product were combined, the solvent 
removed and the pure product 2.2 was left to dry under vacuum. The desired product was isolated as an 
orange crystalline solid. Yield: 0.903 g, 91.2 %. Mp: 49 – 51 °C (lit. 48 – 50 °C). 1H NMR (400.22 




MHz, CDCl3): δ (ppm) = 6.46 (dd, 1H, 3J = 17.5, 3J = 10.7 Hz, He), 5.35 (dd, 1H, 3J = 17.5, 2J = 1.6 
Hz, Hf), 5.03 (dd, 1H, 3J = 10.7, 2J = 1.6 Hz, Hf), 4.36 (t, 2H, 3J = 1.8 Hz, Hc), 4.21 (t, 2H, 3J = 1.8 Hz, 
Hb), 4.11 (s, 5H, Ha). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 134.69 (Ce), 111.06 (Cf), 83.61 
(Cd), 69.2 (Ca), 68.7 (Cb), 66.7 (Cc). IR (KBr, cm-1) ν = 1630 (C=C). Elemental Analysis for C12H12Fe: 
Found C, 67.6; H, 6.03 %; Calculated C, 68.0; H, 5.70 %. EI-MS: m/z 212 ([M]+, 100%). 
 
2.6.3.3 (E)-4-vinylferrocenylbenzaldehyde (2.3)  
 
Compound 2.2 (1.50 g, 7.07 mmol), 4-iodobenzaldehyde (0.684 g, 2.95 mmol), palladium(II) acetate 
(0.0331 g, 0.147 mmol) and tri-o-tolyl-phosphine (0.224 g, 0.767 mmol) were dissolved in a 1:10 
solution of triethylamine and acetonitrile (30 mL). The dark red reaction mixture was stirred under N2 
at 82 °C for 24 hours. After cooling, the solvent removed and resulting red residue was dissolved in 25 
mL of DCM and 25 mL of water added. The organic layer was separated and the aqueous layer washed 
with DCM (3 x 25 mL). The organic (DCM) fractions were combined, stirred over anhydrous MgSO4 
and filtered by gravity. The solvent was removed to give a dark red residue. The product was purified 
by column chromatography, initially using a solvent system of 100% petroleum ether, followed by 
50:50 mixture of petroleum ether (40 – 60 °C) and DCM. The desired product 2.3 was isolated as a dark 
red powder. Yield: 0.680 g, 72.9 %. Mp: decomposition without melting, onset at 110 °C. 1H NMR 
(400.22 MHz, CDCl3): δ (ppm) = 9.97 (s, 1H, Hk), 7.83 (d, 2H, 3J = 8.3 Hz, Hi), 7.56 (d, 2H, 3J = 8.4 
Hz, Hh), 7.07 (d, 1H, 3J = 16.1 Hz, He), 6.73 (d, 1H, 3J = 16.1 Hz, Hf), 4.51 (t, 2H, 3J = 1.8 Hz, Hc), 4.35 
(t, 2H, 3J = 1.8 Hz, Hb), 4.16 (s, 5H, Ha). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 191.55 (Ck), 
144.07 (Cj), 134.67 (Cg), 131.52 (Ce), 130.32 (Ci), 126.07 (Ch), 124.60 (Cf), 82.25 (Cd), 69.76 (Cb), 
69.38 (Ca), 67.37 (Cc). IR (KBr, cm-1) ν = 1693 (C=O), 1630 (C=C). Elemental Analysis for 











2.6.4 Synthesis of Mononuclear Ferrocenyl-imino Complexes 
2.6.4.1 (E,E)-1-propyl-4-vinylferrocenylbenzaldimine (2.4) 
 
n-Propylamine (0.0953 g, 1.61 mmol) dissolved in 10 mL of methanol was added dropwise to a solution 
of 2.3 (0.0509 g, 0.158 mmol) in 20 mL of methanol. The red suspension was stirred at room 
temperature for 24 hours. The solvent of the resulting red solution was reduced to dryness, the residue 
dissolved in DCM and washed using a DCM/water extraction. The organic (DCM) fractions were 
combined, stirred over MgSO4 and filtered by gravity. The solvent of the filtrate was removed to afford 
the desired product 2.4 as a dark red solid residue, which was dried under vacuum. Yield: 0.0468 g, 
82.8 %. M.p: 127.7 – 129.8 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 8.25 (s, 1H, Hk), 7.68 (d, 
2H, 3J = 8.3 Hz, Hi), 7.46 (d, 2H, 3J = 8.3 Hz, Hh), 6.95 (d, 1H, 3J = 16.1 Hz, He), 6.71 (d, 1H, 3J = 16.1 
Hz, Hf), 4.48 (t, 2H, 3J = 1.8, Hc), 4.30 (t, 2H, 3J = 1.8, Hb), 4.15 (s, 5H, Ha), 3.58 (td, 2H, 3J = 7.0, 4J = 
1.2, Hl), 1.74 (m, 2H, Hm), 0.97 (t, 3H, 3J = 7.4, Hn). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 
160.68 (Ck), 140.10 (Cj), 134.79 (Cg), 128.66 (Ce), 128.59 (Ci), 126.02 (Ch), 125.58 (Cf), 83.15 (Cd), 
69.41 (Ca and Cb), 67.18 (Cc), 63.75 (Cl), 24.26 (Cm), 11.99 (Cn). IR (KBr, cm-1) ν = 1628 (C=N), 1598 
(C=C). Elemental Analysis for C22H23FeN.1.5H2O: Found C, 69.10; H, 6.90; N, 2.29 %; Calculated C, 
68.76; H, 6.82; N, 3.64 %. EI-MS: m/z 357 ([M]+, 100%). 
 
2.6.4.2 (E,E)-1-(2,2-dimethyl-1-propyl)-4-vinylferrocenylbenzaldimine (2.5) 
 
2,2-Dimethyl-1-propanamine (0.0266 g, 0.316 mmol) was added dropwise to a solution of 2.3 (0.0503 
g, 0.158 mmol) in 40 mL of methanol. The dark red suspension was stirred under nitrogen at room 
temperature for 48 hours. The solvent of the resulting red solution was reduced to dryness, the residue 
dissolved in DCM and separated by DCM/water extraction, the aqueous layer was washed with DCM 
(3 x 20 mL). The organic (DCM) fractions were collected, stirred over MgSO4, filtered by gravity and 
the solvent of the filtrate removed to afford the desired product 25 as a dark red solid, which was dried 
under vacuum. Yield: 0.0929 g, 95.3 %. Mp: 141.4 – 142.9 °C. 1H NMR (400.22 MHz, CDCl3): δ 
(ppm) = 8.20 (s, 1H, Hk), 7.71 (d, 2H, 3J = 8.3 Hz, Hi), 7.46 (d, 2H, 3J = 8.3 Hz, Hh), 6.95 (d, 1H, 3J = 
16.1 Hz, He), 6.72 (d, 1H, 3J = 16.1 Hz, Hf), 4.48 (t, 2H, 3J = 1.7, Hc), 4.31 (t, 2H, 3J = 1.7 Hz, Hb), 4.15 




(s, 5H, Ha), 3.37 (d, 2H, 4J = 1.5 Hz, Hl), 1.00 (s, 9H, Hn). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 160.60 (Ck), 140.17 (Cj), 135.09 (Cg), 128.66 (Ce), 128.57 (Ci), 126.00 (Ch), 125.64 (Cf), 83.18 
(Cd), 74.22 (Cm), 69.41 (Ca and Cb), 67.19 (Cc), 32.80 (Cl), 28.16 (Cn). IR (KBr, cm-1) ν =1628 (C=N), 
1598 (C=C). Elemental Analysis for C24H27FeN.0.7H2O: Found C, 72.41; H, 7.27; N, 2.70 %; 
Calculated C, 72.44; H, 7.19; N, 3.52 %. HPLC: > 95 %, tr = 4.94 min. EI-MS: m/z 385 ([M]+, 100%). 
 
2.6.4.3 (E,E)-1-(trimethylsilyl-methyl)-4-vinylferrocenylbenzaldimine (2.6) 
 
(Trimethylsilyl)methylamine (0.131 g, 1.27 mmol) was added dropwise to a solution of 2.3 (0.0812 g, 
0.253 mmol) in 40 mL of methanol. The dark red suspension was stirred under nitrogen at room 
temperature for 48 hours. The solvent of the resulting red solution was reduced to dryness, the residue 
dissolved in DCM and washed using a DCM/water extraction. The organic (DCM) fractions were 
collected and the solvent reduced to afford the desired product 2.6 as a dark red solid, which was dried 
under vacuum. Yield: 0.0905 g, 89.2 %. Mp: 110.4 – 113.2 °C. 1H NMR (400.22 MHz, CDCl3): δ 
(ppm) 8.11 (s, 1H, Hk), 7.65 (d, 2H, 3J = 8.3 Hz, Hi), 7.45 (d, 2H, 3J = 8.3 Hz, Hh), 6.93 (d, 1H, 3J = 
16.1 Hz, He), 6.71 (d, 1H, 3J = 16.1 Hz, Hf), 4.48 (t, 2H, 3J = 1.7 Hz, Hc), 4.30 (t, 2H, 3J = 1.7 Hz, Hb), 
4.14 (s, 5H, Ha), 3.42 (d, 2H, 4J = 1.5 Hz, Hl), 0.09 (s, 9H, Hm). 13C{1H} NMR (100.64 MHz, CDCl3): 
δ (ppm) = 158.04 (Ck), 128.88 (Cj), 128.53 (Cg), 128.33 (Ce), 128.11 (Ci), 126.01 (Ch), 125.67 (Cf), 
83.24 (Cd), 69.41 (Ca), 69.37 (Cb), 67.16 (Cc), 54.74 (Ck), 1.16 (Cl). IR (ATR, cm-1) ν = 1628 (C=N), 
1598 (C=C). Elemental Analysis for C23H27FeN: Found C, 68.73; H, 6.71; N, 2.39 %; Calculated C, 
68.82; H, 6.78; N, 3.49 %. EI-MS: m/z 401 ([M]+, 100%). 
 
2.6.5 Synthesis of Polynuclear Ferrocenyl-imino Complexes 
2.6.5.1 (E,E)-Tris(2-aminoethyl)-4-vinylferrocenylbenzaldimine (2.7) 
 
Tris-(2-aminoethyl)-amine (0.0120 g, 0.0843 mmol) dissolved in 10 mL of methanol was added 
dropwise to a solution of 2.3 (0.0800 g, 0.253 mmol) in 40 mL of methanol and the bright red suspension 
was stirred at 40 °C for 22 hours. The desired product 2.7 formed as an orange precipitate, which was 




collected by suction filtration and washed with petroleum ether. Yield: 0.0813 g, 92.6 %. Mp: 115 – 
116 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 8.07 (s, 3H, Hk), 7.48 (d, 6H, 3J = 8.3 Hz, Hi), 7.40 
(d, 6H, 3J = 8.4 Hz, Hh), 6.95 (d, 3H, 3J = 16.1 Hz, He), 6.72 (d, 3H, 3J = 16.1 Hz, Hf) 4.48 (t, 6H, 3J = 
1.7 Hz, Hc), 4.31 (t, 6H, 3J = 1.7 Hz, Hb), 4.15 (s, 15H, Ha), 3.69 (t, 6H, 3J = 6.2 Hz, Hl), 2.95 (t, 6H, 3J 
= 6.1 Hz, Hk). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 161.74 (Ck), 140.21 (Cj), 134.87 (Cg), 
128.67 (Ce), 128.58 (Ci), 126.00 (Ch), 125.60 (Cf), 83.13 (Cd), 69.44 (Ca and Cb), 67.22 (Cc), 60.46 (Cl), 
55.98 (Cm). IR (ATR, cm-1) ν = 1631 (C=N), 1598 (C=C). Elemental Analysis for C63H60Fe3N4: Found 
C, 71.89; H, 5.83; N, 4.58 %; Calculated C, 72.71; H, 5.81; N, 5.38 %. HR-ESI-MS: m/z 1041.2966 
([M+H]+, 54 %), m/z 521.1527 ([M+2H]2+, 100 %), m/z 347.7709 ([M+3H]3+, 64 %).  
 
2.6.5.2 (E,E)-1-DAB-4-vinylferrocenylbenzaldimine (2.8) 
 
DAB-G1-(NH2)4 (0.0205 g, 0.0632 mmol) dissolved in 10 mL of methanol was added dropwise to a 
solution of 2.3 (0.0799 g, 0.253 mmol) in 40 mL of methanol and the bright red suspension was stirred 
at 40 °C for 36 hours. The desired product 2.8 formed as an orange precipitate, which was collected by 
suction filtration and washed with petroleum ether (40 – 60 °C). Yield: 0.0847 g, 88.8 %. Mp: 109 – 
111 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 8.24 (s, 4H, Hk), 7.66 (d, 8H, 3J = 8.3 Hz, Hi), 7.43 
(d, 8H, 3J = 8.4 Hz, Hh), 6.93 (d, 4H, 3J = 16.1 Hz, He), 6.69 (d, 4H, 3J = 16.1 Hz, Hf) 4.46 (t, 8H, 3J = 
1.7 Hz, Hc), 4.30 (t, 8H, 3J = 1.7 Hz, Hb), 4.14 (s, 20H, Ha), 3.63 (t, 8H, 3J = 7.0 Hz, Hl), 2.52 (t, 8H, 3J 
= 7.0 Hz, Hn), 2.43 (m, 4H, Ho), 1.85 (m, 8H, Hm), 1.45 (m, 4H, Hp). 13C{1H} NMR (100.64 MHz, 
CDCl3): δ (ppm) = 160.74 (Ck), 140.08 (Cj), 134.77 (Cg), 128.47 (Ce and Ci), 126.06 (Ch), 125.47 (Cf), 
83.02 (Cd), 69.27 (Ca and Cb), 67.06 (Cc), 59.81 (Cn), 54.14 (Cl), 51.74 (Co), 28.46 (Cm), 25.28 (Cp). IR 
(ATR, cm-1) ν = 1631 (C=N), 1600 (C=C). Elemental Analysis for C92H96Fe4N6.H2O: Found C, 72.45; 
H, 6.61; N, 4.75 %; Calculated C, 72.36; H, 6.47; N, 5.50 %. HR-ESI-MS: m/z 399.2807 










2.6.5.3 (E,E)-1-DAB-4-vinylferrocenylbenzaldimine (2.9) 
 
DAB-G2-(NH2)8 (0.0205 g, 0.0632 mmol) dissolved in 10 mL of methanol was added dropwise to a 
solution of 2.3 (0.0799 g, 0.253 mmol) in 40 mL of methanol and the bright red suspension was stirred 
at 40 °C for 36 hours. The solvent was removed and the resulting orange residue dissolved in a minimum 
amount of DCM. The dark red solution was added dropwise to a large excess of petroleum ether (40 – 
60 °C). The desired product 2.9 formed as an orange precipitate, which was collected by suction 
filtration and dried under vacuum. Yield: 0.0594 g, 47.6 %. Mp: 78 – 80 °C. 1H NMR (400.22 MHz, 
CDCl3): δ (ppm) = 8.22 (s, 8H, Hk), 7.64 (d, 16H, 3J = 8.3 Hz, Hi), 7.41 (d, 16H, 3J = 8.4 Hz, Hh), 6.91 
(d, 8H, 3J = 16.1 Hz, He), 6.68 (d, 8H, 3J = 16.1 Hz, Hf) 4.45 (t, 16H, 3J = 1.7 Hz, Hc), 4.29 (t, 16H, 3J 
= 1.8 Hz, Hb), 4.13 (s, 40H, Ha), 3.61 (t, 16H, 3J = 6.6 Hz, Hl), 2.52 (br m, 16H, Hn), 2.43 (br m, 20H, 
Ho and Hq and Hr), 1.84 (br m, 16H, Hm), 1.68 (m, 16H, Hp), 1.42 (br m, 4H, Hs). 13C{1H} NMR (100.64 
MHz, CDCl3): δ (ppm) = 160.83 (Ck), 140.19 (Cj), 134.92 (Cg), 128.63 (Ce and Ci), 126.05 (Ch), 125.63 
(Cf), 83.17 (Cc), 69.42 (Ca and Cb), 67.21 (Cc), 59.99 (Cm), 54.48, 52.53 (Ck), 51.92 (Cl/n), 41.00, 28.63 
(Co/p), 25.36, 24.90. IR (ATR, cm-1) ν = 1631 (C=N), 1600 (C=C). Elemental Analysis for 
C192H208Fe8N14.2.5H2O: Found C, 71.81; H, 6.79; N, 5.80 %; Calculated C, 71.98; H, 6.70; N, 6.12 %. 
HR-ESI-MS: m/z 1061.3795 ([M+2H+Na]3+, 35 %). 
 
2.6.6 Synthesis of Mononuclear Ferrocenyl-amino Complexes 
2.6.6.1 (E)-1-propyl-4-vinylferrocenylbenzaldamine (2.10) 
 
n-Propylamine (0.187 g, 3.16 mmol) dissolved in 10 mL of methanol was added dropwise to a solution 
of 2.3 (0.101 g, 0.319 mmol) in 30 mL of methanol. The red suspension was stirred at 40 °C for 24 
hours. The solvent of the resulting dark red suspension was reduced to dryness and the residue dissolved 
in 25 mL of dichloromethane. Sodium borohydride (0.0510 g, 1.32 mmol) was then added under N2 at 
0 °C, followed by 5 mL of methanol. The cloudy red solution was warmed to room temperature and 




stirred for 5 hours, after which the solution became clear and bright orange in colour. The solution was 
then quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) reduced and the resulting 
solution was washed using a DCM/water extraction. The organic (DCM) fractions were collected and 
the solvent reduced to afford the desired product 2.10 as a bright red-orange powder, which was dried 
under vacuum. Yield: 0.103 g, 99.4 %. Mp: 89.5 – 92.1 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) 
= 7.40 (d, 2H, 3J = 8.1 Hz, Hi), 7.30 (d, 2H, 3J = 8.3 Hz, Hh), 6.86 (m, 1H, He), 6.68 (m, 1H, Hf), 4.46 
(t, 2H, 3J = 1.8 Hz, Hc), 4.28 (t, 2H, 3J = 1.8 Hz, Hb), 4.13 (s, 5H, Ha), 3.79 (s, 2H, Hk), 2.62 (t, 2H, 3J 
= 7.2 Hz, Hm), 1.57 (m, 2H, Hn), 0.93 (t, 3H, 3J = 7.3 Hz, Ho). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 138.70 (Cj), 136.92 (Cg), 128.75 (Ci), 126.77 (Ce), 125.96 (Cf), 125.92 (Ch), 83.55 (Cd), 69.33 
(Ca), 69.12 (Cb), 66.97 (Cc), 53.70 (Ck), 51.22 (Cm), 23.10 (Cn), 11.89 (Co). IR (ATR, cm-1) ν = 1611 
(C=C), 3298, 1631 (N-H). EI-MS: m/z 359 ([M]+, 100%). Elemental Analysis for C22H25FeN.H2O: 
Found C, 70.31; H, 7.73; N, 2.86 %; Calculated C, 70.03; H, 7.21; N, 3.71 %. HPLC: > 95 % purity, tr 
= 4.10 min.  
 
2.6.6.2 (E)-1-(2,2-dimethyl-1-propyl)-4-vinylferrocenylbenzaldamine (2.11) 
 
2,2-Dimethyl-1-propanamine (0.112 g, 1.28 mmol) was added dropwise to a solution of 2.3 (0.0800 g, 
0.253 mmol) in 30 mL of methanol. The red suspension was stirred under N2 at 40 °C for 24 hours. The 
solvent of the resulting dark red suspension was removed and the residue dissolved in 25 mL of 
dichloromethane. Sodium borohydride (0.0383 g, 1.01 mmol) was then added under N2 at 0 °C, 
followed by 5 mL of methanol. The cloudy red solution was warmed to room temperature and stirred 
for 5 hours, after which the solution became clear and bright orange in colour. The solution was then 
quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) reduced and the resulting solution 
was washed using a DCM/water extraction. The organic (DCM) fractions were collected and the solvent 
reduced to afford the desired product 2.11 as a bright red-orange powder, which was dried under 
vacuum. Yield: 0.115 g, 94.2 %. M.p: 95.9 – 98.0 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 7.40 
(d, 2H, 3J = 8.1 Hz, Hi), 7.29 (d, 2H, 3J = 8.3 Hz, Hh), 6.86 (d, 1H, 3J = 16.1 Hz, He), 6.70 (d, 1H, 3J = 
16.2 Hz, Hf), 4.46 (t, 2H, 3J = 1.8 Hz, Hc), 4.28 (t, 2H, 3J = 1.8 Hz, Hb), 4.14 (s, 5H, Ha), 3.80 (s, 2H, 
Hk), 2.37 (s, 1H, Hm), 0.93 (s, 9H, Ho). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 139.84 (Cj), 
136.68 (Cg), 128.44 (Ci), 126.54 (Ce), 126.10 (Cf), 125.88 (Ch), 83.68 (Cc), 69.33 (Ca), 69.08 (Cb), 66.97 
(Cc) 61.79 (Ck), 54.61 (Cm), 31.67 (Cn), 27.95 (Co). IR (ATR, cm-1) ν = 1607 (C=C), 3279, 1633 (N-




H). EI-MS: m/z 387 ([M]+, 100%). Elemental Analysis for C24H29FeN.0.5H2O: Found C, 72.46; H, 
7.62; N, 3.07 %; Calculated C, 72.73; H, 7.63; N, 3.53 %. 
 
2.6.6.3 (E)-1-(trimethylsilyl-methyl)-4-vinylferrocenylbenzaldamine (2.12) 
 
Trimethylsilane-1-methylamine (0.131 g, 1.27 mmol) was added dropwise to a solution of 2.3 (0.0800 
g, 0.253 mmol) in 30 mL of methanol. The red suspension was stirred under at 40 °C for 24 hours. The 
solvent of the resulting dark red suspension was removed and the residue dissolved in 25 mL of 
dichloromethane. Sodium borohydride (0.0400 g, 1.06 mmol) was then added under N2 at 0 °C, 
followed by 5 mL of methanol. The cloudy red solution was warmed to room temperature and stirred 
for 5 hours, after which the solution became clear and bright orange in colour. The solution was then 
quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) reduced and the resulting solution 
was washed using a DCM/water extraction. The organic (DCM) fractions were collected and the solvent 
reduced to afford the desired product 2.12 as a bright red-orange powder, which was dried under 
vacuum. Yield: 0.101 g, 79.4 %. M.p: 63.6 – 66.2 °C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 7.40 
(d, 2H, 3J = 8.1 Hz, Hi), 7.30 (d, 2H, 3J = 8.3 Hz, Hh), 6.86 (d, 1H, 3J = 16.1 Hz, He), 6.69 (d, 1H, 3J = 
16.1 Hz, Hf), 4.46 (t, 2H, 3J = 1.8 Hz, Hc), 4.28 (t, 2H, 3J = 1.8 Hz, Hb), 4.13 (s, 5H, Ha), 3.81 (s, 2H, 
Hk), 2.08 (s, 2H, Hm), 0.07 (s, 9H, Hn). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 138.82 (Cj), 
136.96 (Cg), 128.72 (Ci), 126.80 (Ce), 126.08 (Cf), 125.99 (Ch), 83.58 (Cd), 69.34 (Ca), 69.12 (Cb), 66.99 
(Cc), 52.89 (Ck), 29.83 (Cm), 1.17 (Cn). IR (ATR, cm-1) ν = 1607 (C=C), 3283, 1631 (N-H). EI-MS: 
m/z 403 ([M]+, 100%). Elemental Analysis for C23H29FeNSi.0.25CH2Cl2: Found C, 65.88; H, 6.71; N, 
1.95 %; Calculated C, 65.76; H, 7.00; N, 3.30 %. 
 
  




2.6.7 Synthesis of Polynuclear Ferrocenyl-amino Complexes 
2.6.7.1 (E)-1-Tris(2-aminoethyl)-4-vinylferrocenylbenzaldamine (2.13) 
 
Tris-(2-aminoethyl)-amine (0.0120 g, 0.0843 mmol) dissolved in 10 mL of methanol was added 
dropwise to a solution of 2.3 (0.0801 g, 0.253 mmol) in 40 mL of methanol. The bright red suspension 
was stirred at 40 °C for 24 hours. The solvent of the resulting red-orange suspension was removed and 
the residue dissolved in 25 mL of dichloromethane. Sodium borohydride (0.0504 g, 1.32 mmol) was 
then added under N2 at 0 °C, followed by 5 mL of methanol. The cloudy red solution was warmed to 
room temperature and stirred for overnight, after which the solution became clear and bright red in 
colour. The solution was then quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) 
reduced and the resulting solution was washed using a DCM/water extraction. The organic (DCM) 
fractions were collected and the solvent reduced to afford the desired product 2.13 as a bright red-orange 
solid. This solid was washed with petroleum ether (40 – 60 °C) to afford an orange precipitate, the 
desired compound 2.13, which was collected by suction filtration. Yield: 0.104 g, 78.7 %. Mp: 65 – 66 
°C. 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 7.35 (d, 2H, 3J = 8.1 Hz, Hi), 7.23 (d, 2H, 3J = 7.1 Hz, 
Hh), 6.84 (d, 1H, 3J = 16.2 Hz, He), 6.68 (d, 1H, 3J = 16.2 Hz, Hf), 4.44 (t, 2H, 3J = 1.8 Hz, Hc), 4.27 (t, 
2H, 3J = 1.8 Hz, Hb), 4.12 (s, 5H, Ha), 3.74 (s, 2H, Hk), 2.69 (t, 6H, 3J = 5.8 Hz, Hm), 2.61 (t, 6H, 3J = 
5.6 Hz, Hn). 13C{1H} NMR (100.64 MHz, CDCl3): 136.94 (Cj), 128.75 (Cg), 128.71 (Ci), 126.85 (Ce), 
126.02 (Ch), 125.95 (Cf), 83.55 (Cd), 69.35 (Ca), 69.13 (Cb), 67.03 (Cc), 54.41 (Cm), 53.71 (Ck), 47.16 
(Cn). IR (ATR, cm-1) ν = 1609 (C=C), 3283, 1631 (N-H). Elemental Analysis for 
C63H66Fe3N4.0.25H2O: Found C, 72.29; H, 6.36; N, 5.35; Calculated C, 71.98; H, 6.38; N, 5.33%. HR-
ESI-MS: m/z 1079.3688 ([M+CH3OH+H]+, 10 %). 
 
2.6.7.2 (E)-1-DAB-4-vinylferrocenylbenzaldamine (2.14) 
 
DAB-G1-(NH2)4 (0.0205 g, 0.0632 mmol) dissolved in 10 mL of methanol was added dropwise to a 
solution of 2.3 (0.0801 g, 0.253 mmol) in 30 mL of methanol and the bright red suspension was stirred 
at 40 °C for 24 hours. The solvent of the resulting orange suspension was removed and the residue 




dissolved in 25 mL of dichloromethane. Sodium borohydride (0.0503 g, 1.32 mmol) was then added 
under N2 at 0 °C, followed by 5 mL of methanol. The cloudy red solution was warmed to room 
temperature and stirred overnight, after which the solution became clear and bright red in colour. The 
solution was then quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) reduced and 
the resulting solution was washed using a DCM/water extraction. The organic (DCM) fractions were 
collected and the solvent reduced to afford the desired product 2.14 as a bright red-orange sticky residue. 
This solid was redissolved in a minimum amount of DCM and added dropwise to a reservoir of hexane. 
An orange precipitate, the desired compound 2.14, formed, which was collected by suction filtration. 
Yield: 0.0530 g, 55.5 %. Mp: 68 – 71 °C 1H NMR (400.22 MHz, CDCl3): δ (ppm) = 7.38 (d, 8H, 3J = 
8.0 Hz, Hi), 7.26 (d, 8H, 3J = 8.3 Hz, Hh), 6.84 (d, 4H, 3J = 16.1 Hz, He), 6.68 (d, 4H, 3J = 16.1 Hz, Hf), 
4.44 (t, 8H, 3J = 1.8 Hz, Hc), 4.27 (t, 8H, 3J = 1.8 Hz, Hb), 4.12 (s, 20H, Ha), 3.74 (s, 8H, Hk), 2.64 (m, 
8H, Hm), 2.45-2.39 (overlapping m, 12H, Ho and Hp), 1.65 (br m, 8H, Hn), 1.38 (br m, 4H, Hq). 13C{1H} 
NMR (100.64 MHz, CDCl3): δ (ppm) = 139.14 (Cj), 136.84 (Cg), 128.70 (Ci), 128.65 (Ce), 126.72 (Cf), 
125.97 (Ch), 83.62 (Cd), 69.35 (Ca), 69.12 (Cb), 67.01 (Cc), 54.23 (Cp) , 53.99 (Ck), 52.60 (Co), 48.25 
(Cm), 27.56 (Cn), 25.18 (Cq). IR (ATR, cm-1) ν = 1609 (C=C), 3302, 1633 (N-H). Elemental Analysis 
for C92H104Fe4N6.4H2O: Found C, 69.05; H, 6.90; N, 4.89 %; Calculated C, 69.63; H, 7.10; N, 5.29 %. 
HR-ESI-MS: m/z 759.2933 ([M+2H]2+, 42 %). 
 
2.6.7.3 (E)-1-DAB-4-vinylferrocenylbenzaldamine (2.15) 
 
DAB-G2-(NH2)8 (0.0397 g, 0.0514 mmol) dissolved in 10 mL of methanol was added dropwise to a 
solution of 2.3 (0.130 g, 0.411 mmol) in 30 mL of methanol and the bright red suspension was stirred 
at 40 °C for 24 hours. The solvent of the resulting orange suspension was removed and the residue 
dissolved in 25 mL of dichloromethane. Sodium borohydride (0.0630 g, 1.67 mmol) was then added 
under N2 at 0 °C, followed by 5 mL of methanol. The cloudy red solution was warmed to room 
temperature and stirred for overnight, after which the solution became clear and bright red in colour. 
The solution was then quenched with 15 mL of water at 0 °C, the solvent (DCM and MeOH) reduced 
and the resulting solution was washed using a DCM/water extraction. The organic (DCM) fractions 
were collected and the solvent reduced to afford the desired product 2.15 as a bright red-orange sticky 
residue. This solid was redissolved in a minimum amount of DCM and added dropwise to a reservoir 
of hexane. An orange precipitate, the desired compound 2.15, formed, which was collected by suction 




filtration. Yield: 0.0747 g, 45.8 %. Yield: 0.0826 g, 50.6 %. Mp: 92 – 94 °C. 1H NMR (400.22 MHz, 
CDCl3): δ (ppm) = 7.37 (d, 16H, 3J = 6.8 Hz, Hi), 7.25 (d, 16H, 3J = 6.8 Hz, Hh), 6.84 (d, 8H, 3J = 16.0 
Hz, He), 6.68 (d, 8H, 3J = 16.0 Hz, Hf), 4.44 (t, 16H, 3J = 1.8 Hz, Hc), 4.27 (t, 16H, 3J = 1.8 Hz, Hb), 
4.12 (s, 40H, Ha), 3.73 (s, 16H, Hk), 2.63 (m, 16H, Hm), 2.46-2.41 (overlapping m, 36H, Ho and Hp and 
Hr and Hs), 1.65-1.57 (br m, 24H, Hn and Hq), 1.41 (m, 4H, Ht). 13C{1H} NMR (100.64 MHz, CDCl3): 
δ (ppm) = 136.83 (Cj), 128.86 (Cg), 128.65 (Ci), 126.73 (Ce), 126.09 (Cf), 125.98 (Ch), 83.60 (Cd), 69.35 
(Ca), 69.13 (Cb), 67.01 (Cc), 53.97 (Co), 53.91 (Ck), 52.51 (Cp), 52.42 (Cr), 48.20 (Cm), 33.98 (Cs), 27.49 
(Cn), 25.48 (Ct), 24.54 (Cq). IR (ATR, cm-1) ν = 1609 (C=C), 3294, 1633 (N-H). Elemental Analysis 
for C192H224Fe8N14.5CH2Cl2: Found C, 65.05; H, 6.83; N, 4.55 %; Calculated C, 65.74; H, 6.55; N, 5.45 
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As previously discussed, the organic scaffolds of drug candidates can be altered or derivatised to 
incorporate biologically active motifs to enhance permeability and retention within biological targets 
and thus augment biological activity. This derivatisation may also improve the chemical and physical 
properties of the compound. One such biologically promising alteration is the use of 
thiosemicarbazones, a class of thioureas which are structurally similar to semicarbazones, all shown in 
Fig. 3.1. Thiosemicarbazones display a broad spectrum of biological activity including antifungal, 
antitumoral, antiviral and antimicrobial activity.1-8 This pharmacological versatility coupled with the 
ease of chemical derivatisation of this group, has led to the widespread use of thiosemicarbazones and 







Fig. 3.1: The general structure of a thiourea (a), thiosemicarbazone (b) and semicarbazone (c). 
Thiacetazone, a thiosemicarbazone-based drug shown in Fig. 3.2, was one of the first commercially 
available for the treatment of tuberculosis.10-12 Used in combination with isoniazid, thiacetazone has a 
mechanism of action similar to that of ethambutol, by which it inhibits cyclopropanation of cell wall 
mycolic acids and thus inhibits cell wall synthesis of Mycobacterium tuberculosis.10-14 The use of this 
drug is declining due to adverse skin reactions and toxicity,10 however, thiosemicarbazone compounds 
continue to be explored in antimycobacterial research.14, 15  
 
Fig. 3.2: Thiosemicarbazone-based anti-TB drug, thiacetazone. 




Transition metal-containing complexes of thiosemicarbazones have also gained great interest, showing 
activity against various microbes, including Mycobacterium tuberculosis.16-22 Klahn and co-workers23 
prepared a series of cyrhetrene- and ferrocene-containing palladium(II) and platinum(II) complexes of 
thiosemicarbazones, an example of which is shown in Fig. 3.3.23 These heterobimetallic complexes 
were evaluated for their in vitro activity against the mc27000 M.tb strain and displayed low to moderate 
micromolar MIC values.23  
 
Fig. 3.3: A ferrocenylthiosemicarbazone-containing palladium(II) complex. 
 
Among their biological applications, thiosemicarbazones have been widely used in antimalarial 
research. An advantage of utilizing thiosemicarbazones against protozoans such as plasmodia is their 
ability to act on targets other than β-haematin, which may result in overcoming drug resistance. 
Thiosemicarbazones have been shown to display antiplasmodial activity through inhibition of cysteine 
proteases, enzymes essential for parasite survival.6 A great body of research has been done on the 
application of mono- and polynuclear transition metal-containing thiosemicarbazone complexes in 
antiplasmodial studies, with some of the most promising results achieved with the incorporation of 
ferrocene.20, 24-27 In addition to its antimycobacterial activity, the complex shown in Fig. 3.3 was also 
among a series of ferrocenylthiosemicarbazone palladium(II) complexes reported to exhibit good 
antiplasmodial activity against both the chloroquine-sensitive (CQS) NF54 and chloroquine-resistant 
(CQR) Dd2 strain.28 
Perhaps most significant to this study, Khanye et al. conjugated ferrocenyl dithiocarbamate ligands to 
the periphery of a polypropyleneimine (PPI) dendrimer scaffold to afford tetranuclear 
ferrocenylthiosemicarbazone complexes, as shown in Fig. 3.4.26 These complexes were evaluated for 
their in vitro activity against the chloroquine-resistant W2 strain, displaying good activity in the low 
micromolar range.26 Stringer et al. prepared mono- and trinuclear analogues of these complexes, which 
displayed low micromolar IC50 values against the chloroquine-resistant Dd2 strain.27 





Fig. 3.4: A tetranuclear ferrocenylthiosemicarbazone complex. 
 
The series of ferrocenyl-imino and amino complexes discussed in Chapter 2 contained ferrocene as a 
possible bioactive moiety, and amines as a drug delivery tool. As an extension to this study, a new series 
of compounds was prepared, conjugating the ferrocenyl-imino complexes with the pharmacologically 
active thiosemicarbazone moiety in order to improve the biological activity as well as the solubility. In 
this chapter, the synthesis and characterisation of these ferrocenylthiosemicarbazone complexes is 
described. The compounds were characterised using a range spectroscopic and analytical techniques. 
 
3.2 Preparation of the dithiocarbamate precursors (3.1 – 3.2) 
 
3.1.1 Synthesis 
Methyl hydrazinecarbodithioate 3.1 was prepared according to a method described by Klayman et al.,3 
by the reaction of hydrazine hydrate with carbon disulfide in the presence of potassium hydroxide in a 
solution of isopropanol and water, followed by the addition of iodomethane. All reagents were added 
at 0 °C.  
 
Scheme 3.1: Preparation of methyl hydrazinecarbodithioate 3.1. 
Compound 3.1 was isolated as a white crystalline solid in 12 % yield, displaying solubility in a range 
of alcoholic solvents, water and partial solubility in organic solvents such as dichloromethane and 
chloroform. The mechanism of this reaction involves the initial formation of a hydrazinecarbodithioate 
salt, followed by methylation of this salt with iodomethane to produce the dithiocarbamate 3.1. 
3.1 
R = H, CH3 




The ferrocenyl dithiocarbamate 3.2 was prepared via a Schiff-base condensation reaction of 2.3 with 
3.1. The reagents were refluxed in isopropanol overnight and 3.2 was obtained in 89 % yield as an 
orange powder, displaying low solubility in polar organic solvents (DCM, chloroform, ethyl acetate) 




Scheme 3.2: Preparation of ferrocenyl dithiocarbamate 3.2. 
 
3.1.2 Characterisation 
1H Nuclear Magnetic Resonance Spectroscopy 
The 1H NMR spectrum of 3.1 (Fig. 3.5) displays a broad singlet at 10.77 ppm, corresponding to the 
hydrazinic proton. The two terminal amine protons give rise to a singlet at 5.06 ppm and the methyl 
protons are observed as a sharp singlet at 2.39 ppm. The highly deshielded nature of the methyl signal 
can be attributed to the electron-withdrawing nature of the adjacent sulfur atom. The integration is 
consistent with the proposed structure. 
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The 1H NMR spectrum of ferrocenyl dithiocarbamate 3.2, shown in Fig. 3.6, confirms imine bond 
formation with the presence of a sharp singlet corresponding to the imine proton at 8.23 ppm. A number 
of signals are retained in this spectrum compared to the spectrum of the aldehyde precursor 2.2. There 
are doublets at 7.66 and 7.59 ppm, respectively, for the two pairs of chemically equivalent protons of 
the 1,4-disubstituted aromatic ring. Each of these aromatic signals have a coupling constant of J ~ 8 
Hz, corresponding to fixed cis configuration of the protons in the ring (see Chapter 2, Fig 2.5). The two 
alkenyl protons are each observed as a doublet (at 7.12 and 6.82 ppm respectively), with vicinal 
coupling constants of J ~ 16 Hz as the double bond has a trans configuration.  
 
 
Fig. 3.6: 1H NMR spectrum of 3.2 in DMSO-d6. 
 
The 1H NMR spectrum displays three peaks for the ferrocenyl protons; a triplet for each of the two 
chemically equivalent pairs of protons of the substituted Cp ring, as well as a singlet for the five protons 
of the unsubstituted Cp ring. Furthermore, a sharp singlet at 2.54 ppm, which integrates for three 
protons, corresponds to the methyl protons of the thioester moiety of 3.2.     
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} NMR spectrum of 3.2 displays the expected number of carbon signals, further confirming 
its chemical structure. The most deshielded peak at 198.43 ppm is attributed to the thiocarbonyl carbon 
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base condensation. The spectrum also displays a peak for each alkenyl carbon atom at 129.78 and 
125.39 ppm respectively. The six aromatic carbon atoms give rise to four signals in the spectrum; two 
quaternary carbon atom signals (140.60 and 126.61 ppm) and two tertiary carbon atom signals (128.36 
and 126.61 ppm), one for each pair of chemically equivalent carbon atoms. The ferrocenyl carbon atoms 
are observed as four signals; a signal at 83.22 for the quaternary carbon, peaks at 69.73 and 67.55 ppm 
for the carbon atoms of the substituted Cp ring and another at 69.56 ppm for the carbon atoms of the 
unsubstituted Cp ring. The carbon atom of the methyl group gives rise to a peak at 17.24 ppm.  
 
Infrared Spectroscopy 
Further evidence supporting the synthesis of precursors 3.1 and 3.2 is provided by infrared (IR) spectral 
data as shown in Fig. 3.7. The IR spectrum of 3.1 displays four absorption bands of interest. The two 
amine groups give rise to ν(N-H) stretching bands at 3262 and 3153 cm-1, and a ν(N-H) bend at 1596 
cm-1. Further to this, ν(C=S) and ν(C-S) absorption bands are observed at 940 cm-1 and 703 cm-1 for the 
thiocarbonyl and thiol groups, respectively.  
 
Fig. 3.7: The infrared spectra of 3.1 (bottom) and 3.2 (top).  





















Some of the absorption bands seen in the IR spectrum of 3.1 are retained in that of 3.2. The thiol ν(C-
S) absorption band is observed at 704 cm-1 and the thiocarbonyl ν(C=S) at 810 cm-1, shifted to a lower 
wavenumber. The amine ν(N-H) stretching band is observed at 3093 cm-1. Evidence of Schiff-base 
condensation is shown by the presence of an imine ν(C=N) absorption band at 1632 cm-1. The alkenyl 
group gives rise to a ν(C=C) stretch at 1591 cm-1. 
 
Mass Spectrometry 
The Electron-Impact mass spectrum of 3.2 further confirms the compound structure, with the base 
peak corresponding to the molecular ion [M]+ at 420.0341 m/z. 
 
 
3.2  Preparation of Mono- and Polynuclear Ferrocenylthiosemicarbazone complexes (3.3 – 3.6) 
3.2.1 Synthesis 
The ferrocenyl dithiocarbamate 3.2 was then used in the synthesis of new mono- and polynuclear 
ferrocenylthiosemicarbazone complexes (3.3 – 3.6). This was achieved by nucleophilic substitution 
reactions of 3.2 with the appropriate amine in dry ethanol under refluxing conditions. The preparation 
of 3.3 is shown in Scheme 3.3.    
 
 
Scheme 3.3: Synthesis of mononuclear ferrocenylthiosemicarbazone complex 3.3. 
 
Interestingly, the mononuclear complex 3.3 was isolated in two different forms. The delocalisation of 
the electron lone pairs of the nitrogen gives rise to thione-thiol tautomerism, as shown in Fig. 3.8. The 
process of tautomerisation results in a shift in the double bond from the thiocarbonyl to the imine and 
a proton transfer from the nitrogen to the sulphur. This can occur in two ways, either delocalisation of 
lone pair electrons from the hydrazinic nitrogen or from the terminal amine group. However, in this 
case the latter has occurred, resulting in the formation of 3.3b. Evidence of this thione-thiol tautomerism 
is seen in the 1H NMR and infrared spectroscopy, discussed later. Thione-thiol tautomerism, similar to 
keto-enol or lactam-lactim tautomerism, has been observed in the literature and is a common 
phenomenon seen in thiosemicarbazones.29-33  
3.2 3.3 






Fig. 3.8: Thione-thiol tautomerism possible for complex 3.3. 
 
Compound 3.3a was obtained as a red-orange powder, while 3.3b was isolated as a dark red-purple 
powder, both displaying solubility in polar organic solvents such as DCM, chloroform and ethyl acetate, 
as well as solubility in alcoholic solvents.  
In a similar procedure to that shown in Scheme 3.3, the polynuclear ferrocenylthiosemicarbzone 
complexes 3.4 – 3.6 were prepared by nucleophilic substitution reactions of 3.2 with tris(2-
aminoethyl)amine or the DAB dendrimer scaffolds (generation 1 and 2) in dry ethanol under refluxing 
conditions, as shown in Scheme. 3.4. These reactions were conducted for long periods due to the poor 
solubility of the ferrocenyl dithiocarbamate 3.2 in ethanol. The trinuclear complex 3.4 was isolated as 
a dark red powder, displaying similar solubility to that of 3.3a and 3.3b. Compounds 3.5 and 3.6, the 
first and second generation dendritic complexes respectively, were obtained as dark orange-brown 
powders, displaying solubility in polar organic solvents such as DCM, chloroform as well as DMSO. 
The polynuclear complexes were isolated in low yields (36 – 43 %). Significantly, these polynuclear 
complexes displayed enhanced solubility in solvents such as DMSO, compared to the non-


















Scheme 3.4: Preparation of polynuclear ferrocenylthiosemicarbazone complexes 3.4 – 3.6. i) tris(2-aminoethyl)-
amine or DAB-Am-4 or DAB-Am-8 / EtOH / 82 °C / 3 days.  
 
The nucleophilic substitution reaction involves the nucleophilic addition of an amine to the thiocarbonyl 
group, followed by the elimination of the -SCH3 to give the thiosemicarbazone product. The mechanism 
of a general nucleophilic substitution reaction is shown in Fig. 3.9. 
 
 
Fig. 3.9: Mechanism of a general nucleophilic substitution reaction. 
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1H Nuclear Magnetic Resonance Spectroscopy 
The 1H NMR spectra of the ferrocenylthiosemicarbazone complexes 3.3a, 3.3b and 3.4 – 3.6, recorded 
in DMSO-d6, all retained several signals seen in the spectrum of the dithiocarbamate precursor 3.2, with 
similar coupling constants and no significant change in chemical shifts and multiplicities. The two 
signals for the four aromatic protons are seen in the range 7.73 – 7.49 ppm, while that of the two alkenyl 
protons is observed between 7.08 and 6.76 ppm. Additionally, the spectra display the three peaks 
corresponding to the ferrocenyl protons between 4.59 and 4.13 ppm.  
 
Significantly, in the 1H NMR spectra of 3.3a and 3.4 – 3.6, the sharp singlet corresponding to the imine 
proton shows a shift upfield from 8.23 ppm in the spectrum of 3.2 to between 8.07 – 8.04 ppm. This is 
expected and can be attributed to the more electron-donating nature of the new amine group compared 
to the –SCH3 group, which it displaces. Further evidence of displacement is shown by the presence of 
a broad signal for the new amine proton in the range 8.55 – 8.44 ppm. In the spectra of 3.3a (Fig. 3.10) 
and 3.5 (Fig. 3.12), the hydrazinic proton is observed as broad singlet at 11.36 and 11.37 ppm, 
respectively. The 1H NMR spectrum (Fig. 3.11) of 3.3b provides evidence that the thiol tautomer is 
present in solution. A sharp singlet corresponding to the imine proton is present at 8.31 ppm, shifted 
significantly downfield compared to that of the thione tautomer 3.3a. This may be a result of the 
accumulative electron-withdrawing effects of the imine (C=N) and thiol (SH) groups, which are not 
present in 3.3a.    
 
 
Fig. 3.10: 1H NMR spectrum of 3.3a in DMSO-d6. 
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Furthermore, the 1H NMR spectra of 3.3a (Fig. 3.10) and 3.3b display three peaks for the protons of 
the propyl chain. The methylene protons adjacent to the amine nitrogen are displayed as a deshielded 
quartet at 3.54 ppm and the methylene protons adjacent to the terminal methyl group give rise to a 
multiplet at 1.63 ppm. The methyl protons are observed as a triplet around 0.90 ppm. 
 
 
Fig. 3.11: Section of the 1H NMR spectrum of 3.3b in DMSO-d6. 
 
In the spectrum of the trinuclear complex 3.4, there are multiplets at 3.75 and 2.87 ppm, respectively, 
corresponding to the methylene protons of the aliphatic branches. The spectrum of 3.5 displays five 
signals for the protons of the aliphatic dendritic core and branches. Peaks at 3.65, 2.45 and 1.75 ppm 
are assigned to the protons of the four branches, while those at 1.37 and 2.30 ppm are assigned to 
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Fig. 3.12: 1H NMR spectrum of 3.5 in DMSO-d6. 
 
The 1H NMR spectrum of 3.6 displays significant broadening of peaks, which can be attributed to 
several protons averaging over the same chemical shift on the NMR timescale, as a result of the 
increased nuclearity of the complex. The eighty protons of the dendritic core and branches give rise to 
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Fig. 3.13: 1H NMR spectrum of 3.6 in DMSO-d6. 
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
The 13C{1H} NMR spectra of 3.3 – 3.6 display all the expected signals. The aromatic ring gives rise to 
two quaternary carbon atom peaks in the region 140.25 – 132.87 ppm, and two tertiary carbon atom 
peaks in the region 128.70 – 126.28 ppm. The two alkene carbon atom peaks are displayed around 129 
and 126 ppm. The carbon atoms of the ferrocenyl Cp rings give rise to a quaternary carbon signal around 
83.37 – 83.33 ppm and three more signals in the region 69.59 – 67.44 ppm. In the 13C{1H} NMR 
spectrum of 3.3b, the peak corresponding to the imine carbon atom adjacent to the phenyl ring appears 
at 160.64 ppm, displaying a considerable shift downfield compared to that of 3.2, which appears at 
146.74 ppm. This trend is also seen in the 1H NMR spectrum and is attributed to the presence of the 
imine and thiol group, which exert electron-withdrawing effects. The carbon atoms of the propyl chain 
give rise to signals at 62.86, 24.19 and 12.19 ppm. 
In the 13C{1H} NMR spectra of 3.4 – 3.6, there is a significant upfield shift in the signal for the thione 
carbon, from 198.43 ppm in the precursor 3.2 to around 177.34 – 177.71 ppm. This can be attributed to 
and gives evidence of the presence of the new amino group, which has a more electron-donating effect 
than the –SCH3 sulfur atom that it replaces. The peak for the imine carbon atom is observed in the range 
142.46 – 142.86 ppm, also showing a slight upfield shift compared to that in 3.2. This is also an effect 
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Furthermore, the carbon atoms of the three aliphatic branches of 3.4 are displayed as two signals (53.14 
and 44.55 ppm). The aliphatic core and branches of 3.5 give rise to peaks at 54.25, 52.19, 43.37, 26.63 
and 25.00 ppm. Similarly, the carbon atoms of the core and branches of 3.6 give rise to five signals in 
the region 52.41 – 24.60 ppm. 
  
Infrared Spectroscopy 
The solid state infrared spectra of 3.3 – 3.6 all display similar absorption bands. The IR spectra of 3.3a, 
3.3b and 3.4 are shown in Fig. 3.14. Most significantly, the absence of the thiol ν(C-S) absorption band, 
which occurs around 703 cm-1 in the precursor 3.2, gives evidence of displacement of the –SCH3 group. 
A strong and sharp thiocarbonyl ν(C=S) stretch is also present at around 810 cm-1 for all complexes. 
This is significant for 3.3b, as it suggests that the thione tautomer is present in the solid state. 
 
Fig. 3.14: The infrared spectrum of the polynuclear complexes 3.3a (bottom), 3.3b (middle) and 3.4 (top). 
 
The amine moieties give rise to ν(N-H) stretching bands in the region 3313 – 3084 cm-1 and ν(N-H) 
bending vibrations between 1528 and 1524 cm-1. The characteristic imine ν(C=N) band is retained in 
these spectra at similar wavenumbers (1630 – 1628 cm-1) as compared to the ferrocenyl dithiocarbamate 
precursor 3.2 (at 1633 cm-1). Furthermore, in each of the spectra the alkenyl group gives rise to an 




























absorption band around 1598 – 1595 cm-1, shifted to slightly higher wavenumbers compared to 3.2. A 
strong and sharp thiocarbonyl ν(C=S) stretch is also present at 810 cm-1.   
 
Mass Spectrometry 
Mass spectral data of 3.3 – 3.6 further confirms the structures of these compounds. The EI mass 
spectrum of 3.3b displays a peak corresponding to the molecular ion [M]+ at m/z 431.0909. The ESI 
mass spectrum of 3.4 shows a base peak corresponding to [M+H]+ (m/z 1263.2756), while the spectrum 
of 3.5 displays a base peak at m/z 903.2354 for [M+2H]2+. In the mass spectrum of 3.6, a peak 





A new ferrocenyl dithiocarbamate (3.2) ligand and four new mono- and polynuclear 
ferrocenylthiosemicarbazone complexes (3.3 – 3.6) were prepared via Schiff-base condensation and 
nucleophilic substitution reactions, respectively. All compounds were characterised using various 
spectroscopic and analytical techniques. The dithiocarbamate 3.2 and polynuclear complexes 3.4 – 3.6 
were found to be stable in air and in solution, as well as at elevated temperatures. The mononuclear 
complex was found to undergo thione-thiol tautomerism and was isolated in both forms. The thiol form 
was isolated as the major product. All complexes displayed similar solubility in solvents such as DCM, 
chloroform and DMSO. However, the mononuclear complexes (3.3a and 3.3b) and the trinuclear 
complex (3.4) were soluble in alcoholic solvents such as ethanol, while the higher generation complexes 











n-Propylamine, tris(2-aminoethyl)-amine, DAB-Am-4, hydrazine hydrate, carbon disulfide and 
iodomethane were purchased from Sigma Aldrich. DAB-Am-8 was purchased from SymoChem. 
Solvents were purchased from Kimix and Merck and ethanol was dried over molecular sieves. Methyl 
hydrazinecarbodithioate (3.1)3 was prepared using a literature procedure. 
 
3.4.2 Spectroscopic and Analytical Techniques 
Infrared (IR) absorptions were measured on a Perkin-Elmer Spectrum 100 FT-IR Spectrometer as KBr 
pellets or using Attenuated Total Reflectance (ATR). Nuclear Magnetic Resonance (NMR) Spectra 
were recorded on a Varian Unity XR400 MHz (1H at 399.95 MHz, 13C at 100.58 MHz), Varian Mercury 
XR300 MHz (1H at 300.08 MHz, 13C at 75.46 MHz) or a Bruker Biospin GmbH (1H at 400.22 MHz, 
13C at 100.64 MHz) spectrometer at 30 °C. Chemical shifts are reported using tetramethylsilane (TMS) 
as the internal standard. Elemental analysis for C, H and N were carried out using a Thermo Flash 1112 
Series CHNS-O Analyser. Mass spectrometry determinations were carried out using Electron Impact 
(EI) on a JEOL GC Matell instrument or High Resolution Electrospray Ionisation (HR-ESI) on a Waters 
API Quattro Micro triple quadrupole mass spectrometer with data recorded using both the positive. 
Melting points were determined using a Reichert-Jung Thermovar or a Büchi Melting Point Apparatus 
B-540.  
 
3.4.3 Synthesis of dithiocarbamate precursors 
3.4.3.1 Methyl hydrazinecarbodithioate (3.1)3 
 
Hydrazine hydrate (6.64 mL) was added to a cooled solution of potassium hydroxide (5.99 g, 0.107 
mmol) in water (25 mL) and isopropanol (25 mL). Ice-cooled carbon disulfide (6.44 mL) was added 
dropwise with stirring, giving rise to a yellow/orange solution. The mixture was stirred for a further 2.5 
hours at room temperature, after which ice-cooled iodomethane (6.64 mL) was added dropwise over a 
1 hour period and the mixture stirred for a further 1.5 hours at room temperature. The clear solution 
was cooled in an ice bath, resulting in the formation of a white precipitate, which was collected by 
suction filtration and washed with cold water. The resulting crude white powder, was recrystallized 
from DCM and collected by suction filtration as a white crystalline solid, the desired product 3.1, which 
was then dried in vacuo. Yield: 1.61 g, 12.3 %. 1H NMR (300.08 MHz, DSMO-d6): δ (ppm) = 10.77 




(br s, 1H, Hb), 5.06 (s, 2H, Ha), 2.39 (s, 3H, Hd). IR (KBr, cm-1) ν = 3262 (N-H), 3153 (N-H), 1505 (N-
H), 703 (C-S).   
 
3.4.3.2 Ferrocenyl dithiocarbamate (3.2) 
 
Compound 3.1 (0.325 g, 2.37 mmol) was added to a stirring solution of 2.3 (0.502 g, 1.58 mmol) in 
isopropanol (50 mL) and the red solution was refluxed for 16 hours, after which an orange precipitate 
had formed. The precipitate was collected by suction filtration and washed with 5 mL of isopropanol. 
The orange precipitate was then dissolved in a minimum amount of DCM and an excess of n-pentane 
was added to precipitate the desired product 3.2 as an orange solid. The product was collected by suction 
filtration and washed with n-pentane. Yield: 0.587 g, 88.5 %. M.p: 184 – 186 °C. 1H NMR (400.22 
MHz, DMSO-d6): δ (ppm) = 8.23 (s, 1H, Hk), 7.68 (d, 2H, 3J = 8.4 Hz, Hi), 7.59 (d, 2H, 3J = 8.3 Hz, 
Hh), 7.12 (d, 1H, 3J = 16.1 Hz, He), 6.82 (d, 1H, 3J = 16.1 Hz, Hf), 4.60 (t, 2H, 3J = 1.8 Hz, Hc), 4.36 (t, 
2H, 3J = 1.8 Hz, Hb), 4.16 (s, 5H, Ha), 2.54 (s, 3H, Hn). 13C{1H} NMR (100.64 MHz, DMSO-d6): δ 
(ppm) = 198.43 (Cm), 146.74 (Ck), 140.60 (Cj), 132.06 (Cg), 129.78 (Ce), 128.36 (Ci), 126.61 (Ch), 
125.39 (Cf), 83.22 (Cd), 69.73 (Cc), 69.56 (Ca), 67.55 (Cb), 17.24 (Cn). IR (KBr, cm-1) ν = 3093 (N-H), 
1633 (C=N), 1591 (C=C), 1521 (N-H), 810 (C=S), 704 (C-S), 1108 (ferrocene). Elemental Analysis 
for C21H20FeN2S2: Found C, 59.47; H, 4.73; N, 5.97; S, 11.63 %; Calculated C, 60.00; H, 4.86; N, 6.66; 
S, 15.25 %. EI-MS: m/z 420.0341 ([M]+, 66.9 %). 
 
3.4.4 Synthesis of Mono- and Polynuclear Ferrocenylthiosemicarbazone complexes 
3.4.4.1 Mononuclear ferrocenylthiosemicarbazone complex (3.3a) 
 
n-Propylamine (0.115 g, 1.93 mmol) was added to a stirring suspension of 3.2 (0.0812 g, 0.193 mmol) 
in 80 mL of dry ethanol and the bright red mixture was refluxed for 24 hours. The solvent of the resulting 
clear red solution was removed and the dark red residue dissolved in 20 mL of dichloromethane and 20 
mL of water was added. The organic (DCM) layer was separated and the aqueous layer washed with 




DCM (3 x 20 mL). The organic fractions were collected, dried over anhydrous sodium sulphate and 
filtered by gravity. The solvent was reduced to about 5 mL and petroleum ether (40 – 60 °C) added to 
precipitate the desired product 3.3a as an orange powder. 1H NMR (300.08 MHz, DMSO-d6): δ (ppm) 
= 11.37 (br s, 1H, Hl), 8.52 (m, 1H, Hn), 8.04 (s, 1H, Hk), 7.73 (d, 2H, 3J = 8.4 Hz, Hi), 7.54 (d, 2H, 3J 
= 8.3 Hz, Hh), 7.06 (d, 1H, 3J = 16.1 Hz, He), 6.83 (d, 1H, 3J = 16.1 Hz, Hf), 4.35 (d, 2H, 3J = 1.8 Hz, 
Hb), 4.59 (d, 2H, 3J = 1.8 Hz, Hc), 4.16 (s, 5H, Ha), 3.54 (m, 2H, Ho),  1.63 (m, 2H, Hp), 0.90 (m, 3H, 
Hq). IR (KBr, cm-1) ν = 3313 (N-H), 3226 (N-H), 1628 (C=N), 1598 (C=C), 1524 (N-H), 810 (C=S), 
1105 (ferrocene).  
 
3.4.4.2 Mononuclear ferrocenylthiosemicarbazone complex (3.3b) 
 
n-Propylamine (0.115 g, 1.93 mmol) was added to a stirring suspension of 3.2 (0.0812 g, 0.193 mmol) 
in 80 mL of dry ethanol and the bright red mixture was refluxed for 24 hours. The solvent of the resulting 
clear red solution was removed and the dark red residue dissolved in 20 mL of dichloromethane and 20 
mL of water was added. The organic (DCM) layer was separated and the aqueous layer washed with 
DCM (3 x 20 mL). The organic fractions were collected, dried over anhydrous sodium sulphate and 
filtered by gravity. The solvent of the filtrate was removed to give the desired compound 3.3b as a red-
purple powder, which was dried in vacuo. Yield: 0.0616 g, 74.0 %. M.p: 117 – 119 °C. 1H NMR (400.22 
MHz, DMSO-d6): δ (ppm) = 8.30 (s, 1H, Hk), 7.69 (d, 2H, 3J = 8.4 Hz, Hi), 7.55 (d, 2H, 3J = 8.3 Hz, 
Hh), 7.08 (d, 1H, 3J = 16.1 Hz, He), 6.81 (d, 1H, 3J = 16.1 Hz, Hf), 4.59 (d, 2H, 3J = 1.8 Hz, Hc), 4.35 
(d, 2H, 3J = 1.8 Hz, Hb), 4.15 (s, 5H, Ha), 3.53 (m, 2H, Ho), 1.65 (m, 2H, Hp), 0.92 (m, 3H, Hq). 13C{1H} 
NMR (100.64 MHz, DMSO-d6): δ (ppm) = 160.64 (Ck),  140.25 (Cj), 135.01 (Cg), 129.20 (Ce), 128.70 
(Ci), 126.28 (Ch), 125.53 (Cf), 83.33 (Cd), 69.59 (Cc), 69.51 (Ca), 67.47 (Cb), 62.86 (Co), 24.19 (Cp), 
12.19 (Cq). IR (KBr, cm-1) ν = 3313 (N-H), 3226 (N-H), 1628 (C=N), 1598 (C=C), 1524 (N-H), 810 
(C=S), 1105 (ferrocene). Elemental Analysis for C23H25FeN3S: Found C, 67.59; H, 7.86; N, 6.65; S, 









3.4.4.3 TRIS-ferrocenylthiosemicarbazone complex (3.4) 
 
Tris(2-aminoethyl)-amine (0.0116 g, 0.0794 mmol) dissolved in 10 mL of dry ethanol was added to a 
stirring suspension of 3.2 (0.105 g, 0.238 mmol) in 100 mL of dry ethanol and the red mixture was 
refluxed for 3 days. The solvent of the resulting red solution was reduced while still warm, giving the 
desired compound 3.4 as a dark red precipitate, which was collected by suction filtration and washed 
with excess n-pentane. Yield: 0.0421 g, 42.0 %. M.p: 158 – 160 °C. 1H NMR (400.22 MHz, DMSO-
d6): δ (ppm) = 11.51 (br s, 3H, Hl), 8.47 (t, 3H, 3J = 5.3 Hz, Hn), 8.05 (br s, 3H, Hk), 7.72 (d, 6H, 3J = 
8.3 Hz, Hi), 7.52 (d, 6H, 3J = 8.3 Hz, Hh), 7.04 (d, 3H, 3J = 16.2 Hz, He), 6.77 (d, 3H, 3J = 16.2 Hz, Hf), 
4.55 (m, 6H, Hc), 4.34 (m, 6H, Hb), 4.13 (s, 15H, Ha), 3.75 (m, 6H, Ho), 2.88 (m, 6H, Hp). 13C{1H} 
NMR (100.64 MHz, DMSO-d6): 177.44 (Cm), 142.47 (Ck), 139.59 (Cj), 132.87 (Cg), 128.98 (Ce), 
128.05 (Ci), 126.42 (Ch), 125.55 (Cf), 83.34 (Cd), 69.63 (Cb), 69.54 (Ca), 67.44 (Cc), 53.14 (Co), 42.55 
(Cp). IR (KBr, cm-1) ν = 3311 (N-H), 3084 (N-H), 1628 (C=N), 1596 (C=C), 1525 (N-H), 809 (C=S), 
1105 (ferrocene). Elemental Analysis for C66H66Fe3N10S3.H2O: Found C, 61.81; H, 5.80; N, 9.93; S, 
4.24 %; Calculated C, 61.88; H, 5.35; N, 10.93; S, 7.51 %. HR-ESI-MS: m/z 1263.2756 ([M+H]+ , 100 
%). 
 
3.4.4.4 DAB-G1-ferrocenylthiosemicarbazone complex (3.5) 
 
DAB-Am-4 (0.0188 g, 0.0595 mmol) dissolved in 10 mL of dry ethanol was added dropwise to a stirring 
suspension of 3.2 (0.102 g, 0.238 mmol) in 100 mL of dry ethanol and the red mixture was refluxed for 
3 days. The resulting red solution was decanted off, leaving as a red/orange oily residue in the flask. 
The oily residue was washed with hot ethanol, dissolved in a minimum amount of DCM and an excess 
amount of n-pentane was added to precipitate the desired compound 3.5 as an orange powder, which 
was collected by suction filtration and dried in vacuo. Yield: 0.0463 g, 43.1 %. M.p: 165 – 167 °C. 1H 
NMR (400.22 MHz, DMSO-d6): δ (ppm) = 11.36 (br s, 4H, Hl), 8.55 (br s, 4H, Hn), 8.07 (br s, 4H, 
Hk), 7.71 (d, 8H, 3J = 8.4 Hz, Hi), 7.52 (d, 8H, 3J = 8.3 Hz, Hh), 7.04 (d, 4H, 3J = 16.1 Hz, He), 6.76 (d, 
4H, 3J = 16.1 Hz, Hf), 4.55 (m, 8H, Hc), 4.33 (m, 8H, Hb), 4.13 (s, 20H, Ha), 3.65 (m, 8H, Ho), 2.45 (m, 




8H, Hq), 2.30 (m, 4H, Hr), 1.75 (m, 8H, Hp), 1.37 (m, 4H, Hs). 13C{1H} NMR (100.64 MHz, DMSO-
d6): δ (ppm) = 177.34 (Cm), 142.46 (Ck), 139.57 (Cj), 132.90 (Cg), 128.97 (Ce), 128.06 (Ci), 126.36 (Ch), 
125.59 (Cf), 83.37 (Cd), 69.59 (Cc), 69.52 (Ca), 67.44 (Cb), 54.25 (Co), 52.19 (Cr), 43.37 (Cq), 26.63 
(Cp), 25.00 (Cs). IR (KBr, cm-1) ν = 3310 (N-H), 3087 (N-H), 1629 (C=N), 1595 (C=C), 1527 (N-H), 
810 (C=S), 1105 (ferrocene). Elemental Analysis for C96H104Fe4N14S4.4H2O: Found C, 61.50; H, 6.30; 
N, 10.77; S, 5.49 %; Calculated C, 61.41; H, 6.01; N, 10.44; S, 6.83 % %. HR-ESI-MS: m/z 903.2354 
([M+2H]2+, 100 %). 
 
3.4.4.5 DAB-G2-ferrocenylthiosemicarbazone complex (3.6) 
 
DAB-Am-8 (0.0231 g, 0.0298 mmol) dissolved in 10 mL of dry ethanol was added dropwise to a stirring 
suspension of 3.2 (0.110 g, 0.238 mmol) in 100 mL of dry ethanol and the red mixture was refluxed for 
3 days. The resulting red solution was decanted off, leaving a red/orange oily residue in the flask. The 
oily residue was washed with hot ethanol, dissolved in a minimum amount of DCM and an excess 
amount of n-pentane was added to precipitate the desired compound 3.6 as an orange/brown powder, 
which was collected by suction filtration and dried in vacuo. Yield: 0.0404 g, 36.2 %. M.p: 168 – 170 
°C. 1H NMR (400.22 MHz, DMSO-d6): δ (ppm) = 8.44 (br s, 8H, Hn), 8.07 (br s, 8H, Hk), 7.67 (d, 
16H, 3J = 8.4 Hz, Hi), 7.49 (d, 16H, 3J = 8.3 Hz, Hh), 7.02 (d, 8H, 3J = 16.1 Hz, He), 6.76 (d, 8H, 3J = 
16.1 Hz, Hf), 4.54 (m, 16H, Hc), 4.32 (m, 16H, Hb), 4.13 (br s, 40H, Ha), 3.65 (m, 16H, Ho), 2.27-2.41 
(br m, 32H, Hq/r/t), 1.75 (br s, 16H, Hp), 1.48 (m, 16H, Hs/u/v). 13C{1H} NMR (100.64 MHz, DMSO-d6): 
177.71 (Cm), 142.86 (Ck), 139.77 (Cj), 132.93 (Cg), 129.04 (Ce), 127.98 (Ci), 126.36 (Ch), 125.64 (Cf), 
83.34 (Cd), 69.57 (Cc), 69.51 (Ca), 67.47 (Cb), 52.41 (Co), 49.56 (Cq), 49.02 (Cr), 43.44 (Cu), 32.02 (Ct), 
26.80 (Cp), 26.37 (Cs), 24.60 (Cv). IR (KBr, cm-1) ν = 3313 (N-H), 3194 (N-H), 1630 (C=N), 1597 
(C=C), 1528 (N-H), 810 (C=S), 1105 (ferrocene). Elemental Analysis for C200H224Fe8N30S8.7H2O: 
Found C, 61.99; H, 6.94; N, 10.48; S, 4.04 %; Calculated C, 61.95; H, 6.19; N, 10.84; S, 6.62 %. HR-
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Antimycobacterial and antiplasmodial evaluation of mono- and 




Tuberculosis and malaria remain highly prevalent microbial diseases, affecting many parts of the world, 
particularly developing countries.1 Although effective drug therapies are currently in use for both 
diseases,2, 3 the emergence of drug resistance has led to the need for the development of new drugs. In 
addition, new drug design strategies have to be explored. 
As mentioned in Chapter 1, the use of ferrocene in therapeutic compounds has proven a promising 
modification. Ferrocene has several properties which lends itself to application in biology.4-6 Perhaps 
most significantly, ferrocene is highly lipophilic and thus can allow the compound to interact with lipid 
layers, such as the cell wall and cell membrane, aiding permeation.4-6 This is particularly important for 
drugs targeting Mycobacterium tuberculosis, as the cell wall and membrane of the bacillus often needs 
to be permeated in order for antimycobacterial action to take place.7, 8 Lipophilicity is also an important 
property in terms of Plasmodium falciparum, allowing the compound to gain access to the digestive 
vacuole of the parasite to prevent pathogenesis. The unique electrochemical properties of ferrocene may 
also allow for the generation of reactive oxygen species (ROS), which are known to have biological 
activity.4-6 A prime example of a promising drug candidate is Ferroquine,9 a chloroquine derivative 
incorporating ferrocene in its side chain, which reached phase IIb clinical trials for malaria.10    
Conjugating the ferrocene moiety to organic scaffolds which would aid in drug delivery and potency, 
is also an important concept to consider. The use of polyamines, an abundant naturally occurring group 
of biomolecules,11-13 may show promise in terms of selective uptake in diseases such as malaria,14, 15 as 
described in Chapter 2. This can be by means of polyamine transporters (PATs). With this in mind, a 
series of ferrocenyl-derived imino and amino complexes, shown in Fig. 4.1, were evaluated as potential 
antimycobacterial and antiplasmodial agents. The imino and amino derivatives were both tested in order 















2.4 and 2.10: R = CH2CH2CH3 
2.5 and 2.11: R = CH2C(CH3)3 






               
     
 
Fig. 4.1: Structures of the ferrocenyl-imine and ferrocenyl-amine complexes screened in antimycobacterial and 
antiplasmodial studies. 
 
The complexes shown in Fig. 4.1 contain a ferrocenyl moiety, for its diverse biological activity, 
lipophilic nature and electrochemical properties. They also contain an alkene and benzyl moiety, further 
increasing the lipophilicity, but which may also be beneficial for binding within biological systems. 
However, these complexes do not contain any known pharmacophore that would impart specific 
biological activity. A pharmacophore that has widespread application in both antimycobacterial and 
antiplasmodial research is the thiosemicarbazone moiety. As mentioned in Chapter 3, one of the first 
known drugs in anti-TB treatment was thiosemicarbazone-based thiacetazone.16-18 In antiplasmodial 
research, thiosemicarbazone-based drug candidates display a unique mechanism of action involving the 
inhibition of cysteine proteases.19 Thus, a second series of ferrocenyl complexes incorporating the 
thiosemicarbazone moiety, as shown in Fig. 4.2, was also evaluated for its antimycobacterial and 
antiplasmodial activity, with the expectation that this derivatisation may result in enhanced biological 
activity compared to the imino and amino complexes.  
2.9 and 2.15: n = 8, 
2.7 and 2.13: n = 3, 
2.8 and 2.14: n = 4, 














Fig. 4.2: Structures of the ferrocenylthiosemicarbazone complexes screened in antimycobacterial and 
antiplasmodial studies.  
3.4: n = 3, 
3.5: n = 4, 
3.6: n = 8, 




4.2 Preliminary Antimycobacterial Studies 
Selected complexes, the mono- and trinuclear ferrocenyl-imino 2.4 – 2.7, the ferrocenyl-amino 2.10 – 
2.12 and all of the ferrocenylthiosemicarbazone complexes 3.3 – 3.6 were evaluated for their 
antimycobacterial activity against the H37Rv strain of Mycobacterium tuberculosis, by determination 
of their minimum inhibitory concentration (MIC) values. The MIC is the lowest concentration of an 
antimicrobial that will inhibit the visible growth of an organism. The MIC90 refers to the concentration 
that inhibits 90 % of the bacterial isolate growth. In this study, the current anti-TB drug rifampicin was 
used as a control, as well as ethambutol, which is some-what structurally similar to the compounds 
being tested. 
 
4.2.1 Antimycobacterial evaluation of ferrocenyl-derived imino complexes (2.4 – 2.9) 
The results of the antimycobacterial screening of the ferrocenyl-derived imino complexes are 
summarised in Table 4.1. 
Table 4.1: MIC90 values obtained for the in vitro studies of the ferrocenyl-imino complexes 2.4 – 2.9, 
as well as rifampicin (RIF) and ethambutol (EMB). 
Compound Nuclearity (n) H37Rv MIC90* (μM) 
2.4 1 37.7 
2.5 1 31.4 
2.6 1 33.1 
2.7 3 19.2 
2.8 4 ND** 
2.9 8 ND** 
EMB - 9.54 
RIF - 0.0249 
*MIC90 is the concentration that inhibits 90 % of bacterial isolate growth. 
**ND = Not determined due to low solubility in the test medium. 
 
All compounds displayed moderate micromolar MIC values. Looking at the MIC90 values, the three 
mononuclear complexes 2.4 – 2.6 displayed similar values (31.4 – 37.7 μM), thus exhibiting similar 
activity. The incorporation of the lipophilic silicon moiety in 2.6 compared to the carbon analogue 2.5 
does not have an effect on its activity. The trinuclear complex 2.7 exhibited the highest 
antimycobacterial activity with the lowest MIC90 value of 19.2 μM, which is 2-fold higher than that of 
the clinically used antimycobacterial drug ethambutol (MIC90 = 9.54 μM). The MIC values for the 




polynuclear complexes 2.8 (n = 4) and 2.9 (n = 8) could not be determined as they were not soluble at 
the tested concentration.   
 
4.2.2 Antimycobacterial evaluation of ferrocenyl-derived amino complexes (2.10 – 2.15) 
In order to compare the effect of the imino group versus the amino group on the antimycobacterial 
activity, the corresponding ferrocenyl-amino derivatives were also screened against the H37Rv 
mycobacterial strain. The results of the in vitro assays of complexes 2.10 – 2.15 are summarised in 
Table 4.2. 
 
Table 4.2: MIC90 values obtained for the in vitro studies of the ferrocenyl-amino complexes (2.10 – 
2.15). 
Compound Nuclearity (n) H37Rv MIC90* (μM) 
2.10 1 ˃ 500 
2.11 1 251 
2.12 1 ˃ 500 
2.13 3 265 
2.14 4 ND** 
2.15 8 ND** 
EMB - 9.54 
RIF - 0.0249 
*ND = Not determined due to low solubility in the test medium. 
*MIC90 is the concentration that inhibits 90 % of bacterial isolate growth. 
 
Overall, the ferrocenyl-amino complexes exhibited little to no antimycobacterial activity, displaying 
high micromolar MIC values (˃ 251 μM). In this series, the carbon analogue 2.11 displayed greater 
activity (MIC90 = 251 μM) than the silicon analogue 2.12, which was not active (MIC90 > 500 μM). The 
mononuclear complex 2.11 and trinuclear complex 2.13 were the most active of the series, displaying 
similar MIC90 values (251 and 265 μM). Once again, the MIC values for the polynuclear complexes 
2.14 (n = 4) and 2.15 (n = 8) could not be determined as they were not soluble at the tested concentration 
range.    




4.2.3 Antimycobacterial evaluation of ferrocenylthiosemicarbazone complexes (3.3 – 3.6) 
Complexes 3.3 – 3.6 contain the thiosemicarbazone moiety, which is the pharmacophore present in 
Thiacetazone, a known anti-TB drug. Incorporation of this moiety conferred increased solubility to 
these complexes compared to the ferrocenyl-imino and amino complexes. Thus, the mononuclear 
complex as well as all polynuclear complexes were soluble at the desired concentration range and could 
be tested. The results of the in vitro screening of ferrocenylthiosemicarbazones 3.3 – 3.6 as well as the 
ferrocenyl dithiocarbamate precursor 3.2 are summarised in Table 4.3.   
 
Table 4.3: MIC90 values obtained for the in vitro studies of the ferrocenyl dithiocarbamate (3.2) 
ferrocenylthiosemicarbazone complexes (3.3 – 3.6)  
Compound Nuclearity (n) H37Rv MIC90* (μM) 
3.2 1 > 125 
3.3 1 47.0 
3.4 3 70.1 
3.5 4 > 125 
3.6 8 41.7 
EMB - 9.54 
RIF - 0.0249 
*MIC90 is the concentration that inhibits 90 % of bacterial isolate growth. 
 
The ferrocenylthiosemicarbazones were found to exhibit moderate antimycobacterial activity. The 
ferrocenyl dithiocarbamate precursor 3.2 and the tetranuclear complex 3.5 displayed relatively low 
activity with MIC90 values above 125 μM. The trinuclear complex 3.4 exhibited slightly better activity 
(70.1 μM), however, the mononuclear 3.3 and octanuclear complex 3.6 showed the best 








4.2.4 Comparison of Antimycobacterial activity 
A comparison of the antimycobacterial data of the ferrocenyl-imino, ferrocenyl-amino and 
ferrocenylthiosemicarbazone complexes revealed some trends in their activities. A graphical 
representation of the results obtained for the antimycobacterial assays is shown in Fig. 4.3 below. 
 
 
Fig. 4.3: Comparison of in vitro antimycobacterial activity of the ferrocenyl-imino (bottom), amino (top) and 
thiosemicarbazone (middle) complexes 
 
Based on the relatively similar antimycobacterial activity of the mononuclear silicon derivative and its 
carbon analogue in the case of the ferrocenyl-imines and amines, the presence of the silicon in the side 
chain appears to have little influence on the antimycobacterial activity. Thus, the corresponding 
ferrocenylthiosemicarbazone silicon derivative and carbon analogue were not prepared and tested. 
Overall, the ferrocenyl-imines 2.4 – 2.7 exhibited the highest activity of the synthesised compounds, 
displaying MIC90 values similar to that of the ferrocenyl diamines reported by Pelinski and co-
workers.20 The presence of an amine moiety in 2.10 – 2.13, which replaces the imine moiety, resulted 
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The incorporation of the thiosemicarbazone moiety, a known pharmacophore, resulted in increased 
solubility and all complexes 3.3 – 3.6 could be tested. The ferrocenylthiosemicarbazone series displayed 
enhanced activity compared to the amino complexes. However, contrary to what was expected, this 
group did not result in enhanced antimycobacterial activity compared to the ferrocenyl-imino series. 
There appears to be no specific trends in activity with respect to the nuclearity of the complexes; the 
trinuclear complex 2.7 is most active in the imino series (and overall), the mononuclear complex 2.11 
in the amino series and the octanuclear complex 3.6 in the thiosemicarbazone series. Although the 
activity of the ferrocenyl imino complexes was determined to be comparable to that of organometallic 
complexes in the literature, none of them are comparable to clinically used antimycobacterial drugs 
such as ethambutol and rifampicin. 
 
  




4.3 Preliminary Antiplasmodial studies 
The ferrocenyl-imino (2.4 – 2.9), ferrocenyl-amino (2.10 – 2.15) and thiosemicarbazone (3.2 – 3.6) 
complexes were evaluated for their ability to reduce parasitemia in the chloroquine-sensitive (CQS) 
NF54 strain of Plasmodium falciparum at the in vitro level. This was achieved by determination of their 
inhibitory concentration (IC50) values, which is defined as the compounds concentration causing 50 % 
inhibition of parasitemia in vitro. Chloroquine, a quinoline-based antimalarial, and artesunate, an 
artemisinin-derived antimalarial, were used as controls in this biological study.  
 
4.3.1 Antiplasmodial evaluation of ferrocenyl-derived imino complexes (2.4 – 2.9) 
The IC50 values obtained for the antiplasmodial screening of the ferrocenyl-imines, as well as the 
nuclearity of the complexes are summarised in Table 4.4 below. 
 
Table 4.4: IC50 values obtained for the in vitro antiplasmodial evaluation of the ferrocenyl-imino 
complexes 2.4 – 2.9 as well as ferroquine (FQ), chloroquine (CQ) and artesunate. 
Compound Nuclearity (n) NF54 IC50* (μM) 
2.4 1 73.6 ± 12.3 
2.5 1 76.3 ± 16.9 
2.6 1 64.8 ± 11.5 
2.7 3 51.1 ± 8.5 
2.8 4 ˃ 66 
2.9 8 24.7 ± 4.8 
FQ 1 0.0427 ± 0.00991 
CQ - 0.0303 ± 0.0160 
Artesunate - 0.0127 ± 0.00156 
*IC50 is the compound concentration causing 50 % inhibition of parasitemia in vitro. 
 
Complexes 2.4 – 2.9 all displayed moderate antiplasmodial activity, exhibiting IC50 values in the 
micromolar range. The mononuclear complexes 2.4 – 2.6 and the tetranuclear complex 2.8 were the 
least active of the series, displaying IC50 values above 64 μM. It is important to note that the 
mononuclear silicon derivative 2.6 showed better activity than its carbon analogue 2.5, and the highest 
activity of the mononuclear complexes. The trinuclear complex 2.7 exhibited enhanced activity 
compared to the mononuclear complexes, with an IC50 value of 51.1 μM, while the octanuclear complex 
2.9 exhibited the highest activity of the series, displaying an IC50 value of 24.7 μM. Thus, the 
polynuclear complexes exhibited slightly enhanced activity compared to the mononuclear derivatives. 




4.3.2 Antiplasmodial evaluation of ferrocenyl-derived amino complexes (2.10 – 2.15) 
The corresponding ferrocenyl-amino complexes were evaluated for their in vitro antiplasmodial activity 
against the CQS NF54 strain. The effect of the new amine moieties compared to the imine moieties can 
be elucidated by comparison of their IC50 values. The results of the antiplasmodial screening of 2.10 – 
2.15 are summarised in Table 4.5. 
 
Table 4.5: IC50 values obtained for the in vitro antiplasmodial evaluation of the ferrocenyl-amino (2.10 
– 2.15) complexes as well as ferroquine (FQ), chloroquine (CQ) and artesunate. 
Compound Nuclearity (n) NF54 IC50* (μM) 
2.10 1 4.87 ± 0.19  
2.11 1 5.29 ± 0.46 
2.12 1 2.88 ± 0.40 
2.13 3 6.31 ± 0.65 
2.14 4 7.18 ± 1.34 
2.15 8 4.22 ± 0.87 
FQ 1 0.0427 ± 0.00991  
CQ - 0.0303 ± 0.0160 
Artesunate - 0.0127 ± 0.00156 
*IC50 is the compound concentration causing 50 % inhibition of parasitemia in vitro. 
 
Complexes 2.10 – 2.15 all displayed good in vitro antiplasmodial activity, exhibiting IC50 values in the 
low micromolar range. The mononuclear complexes 2.10 and 2.11 showed comparable activity with 
IC50 values of 4.87 and 5.29 μM respectively. The silicon-containing derivative 2.12 displayed better 
activity compared to the carbon analogue 2.11, as well as the highest activity in the series, with an IC50 
value of 2.88 μM. The trinuclear and tetranuclear metallodendrimers 2.13 and 2.14 displayed 
comparable activity (6.31 and 7.18 μM, respectively), which is slightly decreased compared to the 
mononuclear complexes. This decreased activity may be a result of the poor solubility of the 
polynuclear complexes (2.13 – 2.15) in dimethylsulfoxide (DMSO), the solvent used to make the stock 
solutions. However, the octanuclear metallodendrimer 2.15 exhibited the highest activity of the 
polynuclear complexes, displaying an IC50 value of 4.22 μM.  
 
  




4.3.3 Antiplasmodial evaluation of ferrocenylthiosemicarbazone complexes (3.3 – 3.6) 
The thiosemicarbazone moiety is of great interest in antimalarial research due to its inherent biological 
activity and ability to inhibit plasmodial cysteine proteases. Complexes 3.3 – 3.6 contain this 
biologically favourable moiety and were evaluated for their antiplasmodial activity in order to 
determine its effect on activity when incorporated into scaffolds of this type. The results for the 
ferrocenyl dithiocarbamate 3.2 and the ferrocenylthiosemicarbazone complexes 3.3 – 3.6 are 
summarised in Table 4.6. 
 
Table 4.6: IC50 values obtained for the in vitro antiplasmodial evaluation of the 
ferrocenylthiosemicarbazone complexes (3.3 – 3.6). 
Compound Nuclearity (n) NF54 IC50* (μM) 
3.2 1 34.16 ± 2.22 
3.3 1 18.06 ± 2.24  
3.4 3 18.74 ± 3.99 
3.5 4 67.64 ± 11.49 
3.6 8 32.79 ± 0.23 
FQ 1 0.0427 ± 0.00991 
CQ - 0.0303 ± 0.0160 
Artesunate - 0.0127 ± 0.00156 
*IC50 is the compound concentration causing 50 % inhibition of parasitemia in vitro. 
 
The ferrocenyl dithiocarbamate 3.2 and the ferrocenylthiosemicarbazone complexes 3.3 – 3.6 all 
displayed moderate in vitro antiplasmodial activity. The dithiocarbamate ligand 3.2 exhibited moderate 
activity, displaying an IC50 value of 34.2 μM. The higher generation (n = 4, 8) polynucelar complexes 
(3.5 and 3.6) were also found to be moderately active, the octanuclear complex 3.6 (IC50 = 32.8 μM) 
displaying two-fold greater activity than the tetranuclear complex 3.5 (IC50 = 67.6 μM). The 
mononuclear complex 3.3 and trinuclear complex 3.4 exhibited the highest activity in the series, 
displaying comparable IC50 values of 18.1 and 18.7 μM, respectively. The enhanced antiplasmodial 
activity of the mono- and trinuclear complexes suggests that the lower nuclearity complexes are the 
more promising candidates. 
 
  




4.3.4 Comparison of Antiplasmodial activity 
The data obtained from the in vitro antiplasmodial studies of the ferrocenyl-imino, ferrocenyl-amino 
and ferrocenylthiosemicarbazones was collated and compared, revealing some meaningful observations 
and trends in their activities. This comparison is graphically represented in Fig. 4.4 below. 
 
 
Fig. 4.4: Comparison of in vitro antiplasmodial activity of the ferrocenyl-imino (top), amino (bottom) and 
thiosemicarbazone (middle) complexes 
 
Comparison of the IC50 values of the ferrocenyl-imino complexes 2.4 – 2.9 to that of the ferrocenyl-
amino complexes 2.10 – 2.15 revealed that the amino complexes showed superior antiplasmodial 
activity. Specifically, in the case of the mononuclear complexes, the amines 2.10 – 2.12 exhibited at 
least a 15-fold increase in activity compared to the corresponding mononuclear imines 2.4 – 2.6. The 
polynuclear amino complexes 2.13 – 2.15 exhibited at least a 5-fold increase in activity compared to 
the corresponding polynuclear imines 2.7 – 2.9. This suggests that the presence of the amine moiety is 
favourable compared to the imine moiety as it results in greatly enhanced antiplasmodial activity.  
In both series, the silicon-containing mononuclear derivatives (2.6 and 2.12) exhibited enhanced 
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with literature examples of silicon-containing compounds used in pharmacological evaluations.21-23 The 
incorporation of the lipophilic silicon moiety results in an increase in the activity compared to the non-
silicon analogues.21-23 Adams and co-workers reported on the improved antiparasitic (malaria and 
trichomoniasis) activity of ferrocene-containing organometallic compounds by incorporation of silane 
moieties.24   
In the case of the mono- and trinuclear complexes, the ferrocenylthiosemicarbazone complexes (3.3 and 
3.4) exhibited enhanced antiplasmodial activity compared to the ferrocenyl-imino complexes (2.4 and 
2.7), and decreased activity compared to the ferrocenyl-amino complexes (2.10 and 2.13). Interestingly, 
3.3 and 3.4 exhibited similar and improved antiplasmodial activity compared to analogous 
ferrocenylthiosemicarbazone complexes reported by Stringer and co-workers.25 The tetra- and 
octanuclear thiosemicarbazone complexes (3.5 and 3.6) displayed comparable activity to the imino 
complexes (2.8 and 2.9). Consistently for the imino, amino and thiosemicarbazone complexes, the 
tetranuclear complexes (2.8, 2.14 and 3.5) showed the lowest antiplasmodial activity of the polynuclear 
complexes. This suggests that this nuclearity or molecule size is not favourable or optimum for activity. 
The antiplasmodial activity of the synthesised organometallic compounds was much lower than 
clinically used drugs such as the organic-based chloroquine and artesunate. The results also do not 
compare to that of ferroquine, a very promising organometallic antiplasmodial drug candidate. Overall, 
the ferrocenyl-derived amino complexes 2.10 – 2.15 exhibited the highest activity, displaying IC50 
values comparable to other organometallic complexes reported in the literature. It should be noted that 
there are not many examples of antiplasmodial metallodendrimers in the literature and these results are 
promising for the further use of similar compounds in pharmacological studies. 
  




4.4 Experimental  
 
4.4.1 In vitro Pharmacological Evaluation 
4.4.1.1 M. tuberculosis microdilution method 
The minimum inhibitory concentration (MIC) was determined using the standard broth micro dilution 
method, where a 10 ml culture of Mycobacterium tuberculosis H37RvMa::pMSP12GFP,26 was grown 
to an optical density (OD600) of 0.6 – 0.7 in GAST-Fe (glycerol–alanine–salts) medium pH 6.6, 
supplemented with 0.05% Tween-80.27 The culture was then diluted 1:100 in GAST-Fe. The 
compounds to be tested were reconstituted to a concentration of 12.8 mM in DMSO. Duplicate two-
fold serial dilutions of the test compound were prepared in GAST-Fe, across a 96-well micro titre plate, 
after which, 50 μl of the 1:100 diluted M. tuberculosis culture was added to each well in the serial 
dilution. The plate layout was a modification of the method previously described.28 Controls used were 
a minimum growth control (Rifampicin at 2xMIC) a maximum growth control (5% DMSO in GAST-
Fe), Rifampicin and Ethambutol. The micro titre plate was sealed in a secondary container and 
incubated at 37 °C with 5% CO2 and humidification. Relative fluorescence (excitation 485nM; emission 
520nM) was measured using a plate reader (FLUOstar OPTIMA, BMG LABTECH), at day 7 and day 
14. The raw fluorescence data were archived and analysed using the CDD Vault from Collaborative 
Drug Discovery, in which, data were normalised to the minimum and maximum inhibition controls to 
generate a dose response curve (% inhibition), using the Levenberg-Marquardt damped least-squares 
method, from which the MIC90 was calculated.29 The lowest concentration of drug that inhibits growth 
of more than 90 % of the bacterial population was considered to be the MIC90. 
 
4.4.1.2 P. falciparum in vitro assay 
The test samples were tested in triplicate on one occasion against the chloroquine-sensitive NF54 strain. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained using a 
modified method of Trager and Jensen.30 Quantitative assessment of antiplasmodial activity in vitro was 
determined via the parasite lactate dehydrogenase assay using a modified method described by Makler 
et al.31 The test samples were prepared to a 20 mg/cm3 stock solution in 100% DMSO and sonicated to 
enhance solubility. Samples were tested as a suspension if not completely dissolved. Stock solutions 
were stored at -20 °C. Further dilutions were prepared on the day of the experiment. Chloroquine (CQ) 
was used as the reference drug in all experiments. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test samples 
were tested at a starting concentration of 100 μg/cm3, which was then serially diluted 2-fold in complete 
medium to give 10 concentrations, with the lowest concentration being 0.2 μg/cm3. The same dilution 




technique was used for all samples. CQ was tested at a starting concentration of 1000 ng/cm3 against 
the CQS strain. The highest concentration of solvent to which the parasites were exposed had no 
measurable effect on the parasite viability. The IC50 values were obtained using a nonlinear dose-
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Conclusions and Future Work 
 
5.1 Conclusions 
Ferrocene is an organometallic moiety with great potential for application in biology and chemotherapy 
due to its favourable chemical and physical properties. Polyamine-based dendrimers are potential 
bioactive moieties and possess the ability to act as drug transport and delivery scaffolds. Therefore, the 
main focus of this study was to prepare series ferrocenyl-derived metallodendrimers and mononuclear 
analogues, to characterise and evaluate their antimycobacterial and antiplasmodial activity.  
Ferrocene-containing precursors were prepared by Wittig olefination, Heck cross-coupling and Schiff-
base condensation reactions. The preparation of a series of ferrocenyl-imino complexes was achieved 
by Schiff-base condensation reactions of a ferrocenyl aldehyde with various amines. The corresponding 
ferrocenyl amino complexes were prepared via reductive amination reactions from the ferrocenyl 
aldehyde. In addition, a series of ferrocenylthiosemicarbazone complexes were synthesised by 
nucleophilic substitution reactions of a ferrocenyl dithiocarbamate with various amines. All precursors 
and complexes were characterised by various techniques such as 1H, 13C{1H} and 31P{1H} NMR 
spectroscopy, FT-IR spectroscopy, EI- or ESI-mass spectrometry and elemental analysis.   
The synthesised ferrocenyl-imino, ferrocenyl-amino and ferrocenylthiosemicarbazone 
metallodendrimers and mononuclear analogues were evaluated as potential antimycobacterial and 
antiplasmodial agents in preliminary in vitro assays. The compounds were screened for their 
antimycobacterial activity against the H37Rv strain of Mycobacterium tuberculosis. The tetranuclear 
and octanuclear ferrocenyl-imino and amino complexes (2.8, 2.9, 2.14 and 2.15) were not soluble at the 
required concentration and thus could not be evaluated. Two mononuclear ferrocenyl-amino complexes 
(2.10 and 2.12) as well as the tetranuclear thiosemicarbazone complex (3.5) were not active at the tested 
concentrations. The remaining ferrocenyl complexes exhibited moderate to low antimycobacterial 
activity in the micromolar range. The ferrocenyl-amino complexes were the least active in the 
antimycobacterial screening. It is noteworthy that the presence of the silicon moiety in the side chain of 
the mononuclear imino and amino complexes (2.6 and 2.12) did not have a significant effect on the 
antimycobacterial activity compared to their carbon analogues (2.5 and 2.11). In the thiosemicarbazone 
series, the mononuclear complex (3.3) and octanuclear complex (3.6) showed the best activity, the two 
displaying comparable MIC90 values. Again, the low solubility of the polynuclear thiosemicarbazone 
complexes may have hindered their antimycobacterial activity. The ferrocenyl-imino complexes were 




found to exhibit the best antimycobacterial activity overall. The trinuclear imino complex (2.7) 
displayed higher activity (almost two-fold) than the mononuclear complexes (2.4 – 2.6), suggesting a 
correlation between nuclearity and antimycobacterial activity. The ferrocenyl-imino complexes 
displayed activity comparable to that of other organometallic complexes reported in the literature, but 
not comparable to clinically available antimycobacterial drugs. The overall trend observed in the 
antimycobacterial screening can be summarised as shown below. 
ferrocenyl-imino > ferrocenylthiosemicarbazone > ferrocenyl-amino 
 
Additionally, the compounds were evaluated for antiplasmodial activity against the chloroquine-
sensitive (CQS) NF54 strain of Plasmodium falciparum. The tetranuclear imino complex (2.8) was not 
active at the tested concentration. The remaining complexes displayed moderate to good antiplasmodial 
activity in the micromolar range. In the ferrocenyl-imino series, the octanuclear complex (2.9) exhibited 
the best activity, suggesting that the antiplasmodial activity is related to high nuclearity. However, in 
the thiosemicarbazone series, the mono- complex and trinuclear complexes (3.3 and 3.4) showed the 
best activity. The low activity of some of the polynuclear complexes may be a result of their low 
solubility in the DMSO, which was used to make the stock solutions. Contrary to what was observed in 
the antimycobacteral screening, the silicon-containing derivatives (2.6 and 2.12) displayed enhanced 
activity compared to their carbon analogues (2.5 and 2.11). This trend is consistent with what is 
observed in the literature. Overall, the ferrocenyl-amino complexes exhibited the best antiplasmodial 
activity, displaying IC50 values in the low micromolar range. Their activity was determined to be 
comparable to that of other ferrocenyl-derived organometallic complexes reported in the literature. 
However, as seen in the antimycobacterial studies, the IC50 values obtained for the synthesised 
complexes are not comparable to that of clinically available antimalarial drugs. With regard to these 
ferrocenyl complexes, there seemed to be no correlation between nuclearity and antiplasmodial activity. 
The overall trend in activity, which is contrary to what was observed in the antimycobacterial screening, 
can be summarised as shown below. 
ferrocenyl-amino > ferrocenylthiosemicarbazone > ferrocenyl-imino 
 
  




5.2 Future Work 
While some of the complexes prepared in this study exhibited promising biological activity, the activity 
of others may have been hindered by their physical and chemical properties. In terms of the polynuclear 
complexes prepared in this study, the low solubility played a major role in the determination of the 
biological activity. Improving the solubility and perhaps incorporating water-soluble groups to confer 
water-solubility, may improve the biological activity and the chemical properties in general. It has 
widely been observed in the literature that lipophilicity is an important factor in improving biological 
activity in many different microbial diseases. However, water-solubility may also be a favourable 
property in this regard and perhaps a good balance between lipophilicity and water-solubility would 
lead to new interactions in biological systems as well as aiding in permeation of cell walls and 
membranes. 
Since the incorporation of the lipophilic silicon moiety resulted in enhanced antiplasmodial activity in 
this study, future synthetic work could involve the preparation and biological evaluation of carbosilane 
dendrimers. In order to confer water-solubility to the complexes synthesised in this project, the dendritic 
scaffold could be altered to incorporate water-soluble moieties. In this regard, the poly(amidoamine) 
(PAMAM) scaffold could be used. A series of PAMAM analogues of the synthesised complexes could 
be prepared and biologically evaluated, to determine the effect of the water-solubility on the activity. 
In addition, the compounds that displayed good activity in the preliminary biological evaluations could 
be pursued in further tests. The ferrocenyl-derived amino complexes, which displayed promising 
activity against the chloroquine-sensitive (CQS) NF54 strain of Plasmodium falciparum, should be 
evaluated against a chloroquine-resistant (CQR) strain. Mechanistic studies such as β-haematin 
inhibition studies and cysteine protease inhibition studies could be performed in order to determine the 
possible mode of antiplasmodial action.  
